Introduction {#s1}
============

A synapse is a specialized structure where signals are transmitted from a neuron to another neuron or other target cells such as muscles. Proper synapse formation is prerequisite to building functional synapses and constructing neuronal circuits. Synapse abnormalities are suggested to induce neurological and psychological disorders such as autism spectrum disorders and fragile X syndrome ([@bib39]). Formation of postsynapses requires coordinated formation of several specialized structures. One prominent postsynaptic feature at neuromuscular junctions (NMJs) is the extensively folded muscular membranes. Specialized folding of postjunctional membranes is thought to increase the area exposed to the synaptic cleft and ensure the effectiveness of neuromuscular transmission ([@bib34]; [@bib43]). In addition to membrane specializations, the postsynaptic density (PSD) is also a common element whose size requires proper control. The PSD contains scaffolding proteins that recruit signaling protein complexes and neurotransmitter receptors, matching precisely the presynaptic active zones ([@bib13]; [@bib35]). Formations of postsynaptic membrane and PSD are tightly controlled and coordinated yet these processes remain elusive.

The *Drosophila* NMJ is a model to study synapse formation and activity-dependent synapse remodeling ([@bib6]; [@bib33]). Synaptic boutons are swollen structures of axonal terminals embedded in highly folded muscular membranes called the subsynaptic reticulum (SSR) and each bouton contains tens of neurotransmitter release sites paired with PSDs. During larval development, the SSR and the PSD concomitantly form and gradually increase their sizes. Two crucial factors, postsynaptic density protein-95/Discs large (Dlg) localized at the SSR and *Drosophila* p21-activating kinase (dPak) localized at the PSD, regulate SSR formation ([@bib1]; [@bib3]; [@bib28]). At the PSD, two types of localized glutamate receptors (GluRs), IIA and IIB, appear in distinct GluR clusters ([@bib30]). The abundance of GluRIIA at the PSD is regulated by PSD-localized dPak and the SSR-localized NF-κB complex, NF-κB/Dorsal (Dl), IκB/Cactus (Cact) and IRAK/Pelle (Pll) ([@bib1]; [@bib22]; [@bib31]; [@bib45]). Thus, the postsynaptic protein could localize at either SSR or PSD, and confer growth regulation on SSR, PSD or both.

Ubiquitination plays essential roles in various cellular processes including synaptic growth ([@bib10]). Ubiquitin species are dynamically balanced among free and substrate-conjugated forms of mono-ubiquitin and ubiquitin chains. Ubiquitin homeostasis, i.e. the maintenance of diverse ubiquitin species in proper proportions and levels, is regulated in cellular growth and differentiation ([@bib19]; [@bib24]). Deubiquitinases (DUBs), a large superfamily of ubiquitin regulators, participate in the dynamic equilibrium of ubiquitin species. While some DUBs process newly synthesized ubiquitin precursors for ubiquitin supply, others recycle ubiquitin by cleaving ubiquitin chains from protein substrates prior to proteasomal degradation. USP5, the focus of this study, is dedicated to disassembly of free ubiquitin chains for recycling ([@bib23]; [@bib27]). Physiologically, heat shock stress in yeast causes a reduction of the mono-ubiquitin level. To compensate for ubiquitin depletion, the level of the DUB Doa4 is elevated, leading to an increase in the mono-ubiquitin level by cleaving free ubiquitin chains ([@bib25]). The ataxia mice *ax^J^*, carrying mutations in the DUB USP14, displayed nerve swelling and abnormal neurotransmission at NMJs. The defects are caused by a reduction in the ubiquitin level as lower ubiquitin levels were detected in the mutant mice and introducing an ubiquitin transgene suppressed the *ax^J^* phenotypes ([@bib4], [@bib5]). Thus, regulation of the ubiquitin level is a critical step in synapse development and for preventing neurological disorders.

*Drosophila* USP5/Leon is essential to maintain ubiquitin homeostasis during tissue formation and controls activation of apoptosis and the JNK pathway during eye development ([@bib12]; [@bib42]). In this study, we characterized the role of Leon in postsynaptic growth after synapse formation. In *leon* mutants, while the presynapse maintains normal morphology, the postsynapse overelaborates, displaying expanded SSR, enlarged PSD and excess PSD-localized GluR clusters. Free ubiquitin chains and ubiquitinated substrates accumulate in *leon* postsynapses, revealing defects in ubiquitin homeostasis. Genetic analysis shows that accumulations of several postsynaptic proteins accounts for overelaborated postsynaptic structures. The ubiquitin receptor Ubqn recognizes and transfers ubiquitinated substrates to the proteasome for degradation ([@bib15]; [@bib29]). The Ubqn level is elevated in *leon* postsynapses and reducing the Ubqn level suppresses *leon* mutant phenotypes. Importantly, co-overexpression of free ubiquitin chains and Ubqn promotes expansion of these postsynaptic features. Thus, ubiquitin homeostasis such as disassembly of free ubiquitin chains, timely degradation of proteins, and normal function of the ubiquitin receptor Ubqn are compromised in *leon* mutants, leading to postsynaptic overgrowth.

Results {#s2}
=======

Abnormal NMJ morphology in *leon* mutants {#s2-1}
-----------------------------------------

We examined NMJs in third-instar larvae of *leon^2^/19-2* mutants that died at mid-pupal stages and *leon^1^/19-2* mutants that died at the late-third larval stages. Based on the viability and Western blot analysis, *leon^2^/19-2* is considered a hypomorphic mutant and *leon^1^/19-2* is a close-to-null mutant ([@bib42]). Both NMJ phenotypes were compared to the control *w^1118^* that had been used to backcross all *leon* alleles. At control NMJs, axonal terminals immunostained for presynaptic horseradish peroxidase (HRP) branched out extensively from initial targeting sites; synaptic boutons revealed by postsynaptic Dlg staining spread evenly along axonal tracks, displaying the beads-on-a-string pattern ([Figure 1A](#fig1){ref-type="fig"}). In *leon* mutants, axonal terminals failed to extend and synaptic boutons aggregated, making them larger in appearance ([Figure 1A](#fig1){ref-type="fig"}). To quantify the morphological defects, we scored the number of boutons and branch lengths of NMJs at muscles 6/7. In both *leon^1^/19-2* and *leon^2^/19-2* mutants, the bouton numbers were significantly decreased by about 25% ([Figure 1B](#fig1){ref-type="fig"}). Total branch length was also reduced in *leon^1^/19-*2, although the reduction was not significant in *leon^2^/19-2* ([Figure 1C](#fig1){ref-type="fig"}). In both mutants, the muscle sizes were comparable to controls ([Figure 1D](#fig1){ref-type="fig"}). Reductions in both bouton number and branch length in *leon^1^/19-2* were completely restored by *GFP-leon-GR*, a genomic rescue transgene of *leon,* suggesting that *leon* is required for normal NMJ formation ([Figure 1A--C](#fig1){ref-type="fig"}).10.7554/eLife.26886.002Figure 1.*leon* mutants display abnormal NMJ morphology.(**A**) Immunostaining images show NMJs of *w^1118^*, *leon^2^/19-2*, *leon^1^/19-*2 and *GFP-leon-GR*, *leon^1^/19-2* for HRP (red) and Dlg (green). (**B--D**) Bar graphs show means ± SEM (standard error of mean) of bouton numbers (**B**), branch lengths (**C**) and muscle areas (**D**, quantified by phalloidin staining, not shown). (**E** and **G**) Immunostaining images co-stained by HRP (red) and Dlg (green) show transgene rescue of *leon^1^/19-*2 NMJs by *UAS-leon* or *UAS-ED-leon* driven by postsynaptic *24B-GAL4* (**E**) or presynaptic *D42-GAL4* (**G**). (**F** and **H**) Bar graphs show means ± SEM of bouton numbers in postsynaptic or presynaptic rescue. Scale bars, 20 μm. All data were compared to controls unless specifically indicated by brackets, with n.s. indicating no significance, \* for p\<0.05, and \*\*\* for p\<0.001 according to Student's *t* tests. The detail statistic numbers also see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.002](10.7554/eLife.26886.002)10.7554/eLife.26886.003Figure 1---figure supplement 1.Postsynaptic *leon* in NMJ morphology and Leon expression pattern.(**A**,**B**) Immunostaining images co-stained by HRP (red) and Dlg (green) show bouton number reduction in *UAS-leonRNAi* driven by postsynaptic *24B-GAL4* (**A**), but not by presynaptic *D42-GAL4* (**B**). Scale bars, 20 μm. (**C**) Bar graphs show means ± SEM of bouton number in *24B-GAL4*, *24B\>leonRNAi, D42-GAL4,* and *D42\>leonRNAi.* Pairwise comparisons are shown by brackets with n.s. indicating no significance and \*\*\* for p\<0.001 according to Student's *t* tests. The detail statistic numbers also see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. (**D**) Immunostaining images of NMJs for Leon (green) and HRP (red) show that Leon is expressed in muscles and NMJs (arrowhead) of *w^1118^*, and Leon signals are largely diminished in *19-2/19-2*. The single Leon images (right panels) are also shown. Scale bar, 10 μm. (**E**) Enlarged images show expressions of Leon (green) and Cact (red), or Leon only (bottom), in a single bouton. Scale bar, 5 μm. The orange-colored arrow crossing the bouton was quantified for the intensities (gray value) of Cact and Leon (right panel). (**F**) Immunostaining images of NMJs for GFP (green) and Dlg (red) show expressions of *GFP-leon-GR* in *leon^1^/19-2,* similar to endogenous Leon expression. The single GFP image (right) is also shown. Scale bar, 10 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.003](10.7554/eLife.26886.003)

We then analyzed whether *leon* is required in pre- or post-synapses by performing tissue-specific rescue of *leon* mutants. Expression of *UAS-leon* by *24B-GAL4* in muscles of *leon^1^/19-2* restored NMJ morphology and bouton number to the wild-type level ([Figure 1E,F](#fig1){ref-type="fig"}). In contrast, expression by *D42-GAL4* in motor neurons failed to rescue *leon* mutant phenotypes ([Figure 1G,H](#fig1){ref-type="fig"}). The postsynaptic requirement of *leon* was further confirmed by driving the *leonRNAi* transgene in individual compartments. When driven by *24B-GAL4,* the NMJ morphological defect was identical to that of *leon* mutants, with a significant reduction in the bouton number ([Figure 1---figure supplement 1A,C](#fig1s1){ref-type="fig"}). These phenotypes, however, were not detected by neuronal expression of *leonRNAi* ([Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}).

To analyze the requirement of Leon deubiquitinating activity for NMJ growth, the *UAS-ED-leon* transgene that expresses enzyme-dead Leon was introduced into *leon* mutants. Expression of *UAS-ED-leon* in muscles or motor neurons failed to rescue any of the *leon* mutant phenotypes ([Figure 1E--H](#fig1){ref-type="fig"}). Thus, in comparison to the effective rescue by wild-type *UAS-leon*, this result suggests that Leon functions as a DUB in regulating NMJ development.

Immunostaining of larval tissues by anti-Leon antibodies showed that Leon was expressed ubiquitously. At NMJs, Leon was enriched within synaptic boutons ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}, arrowheads). Leon was also expressed in postsynapses with lower levels in the SSR marked by Cact ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). These Leon expressions were almost diminished in the null *19--2* homozygous larvae, confirming that these signals represent Leon expression ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}, bottom panels). Residual puncta (arrowheads) within presynaptic boutons may represent background signals. The genomic rescue transgene *GFP-leon-GR* showed a similar expression pattern to endogenous Leon ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}), further confirming Leon expression at the NMJ.

Defective ubiquitin homeostasis in *leon* postsynapses {#s2-2}
------------------------------------------------------

To examine whether ubiquitin homeostasis is disrupted in the *leon* mutant, we first performed Western blots to analyze ubiquitin profiles in dissected body wall muscles. By blotting with the anti-ubiquitin antibodies, we found that the levels of free ubiquitin chains were increased in *leon* mutants ([Figure 2A](#fig2){ref-type="fig"}). Whereas moderate increases were detected in hypomorphic *leon^2^/19-2* (2.33 ± 0.64 folds, see Materials and methods), large increases were found in null *19-2/19-2* and close-to-null *leon^1^/19-2* (4.25 ± 1.38 and 4.62 ± 1.61 folds, respectively). In addition, smearing signals at higher molecular weights representing ubiquitinated substrates were also increased in *19-2/19-2* and *leon^1^/19-2* (1.88 ± 0.31 and 1.76 ± 0.37 folds, respectively). The higher molecular-weight smears, however, were increased slightly in *leon^2^/19-2* (1.29 ± 0.78 folds). In contrast, the level of monoubiquitin was strongly increased in hypomorphic *leon^2^/19-2* (1.9 ± 0.77 folds) but the increases were not prominent in *19-2/19-2* and *leon^1^/19-2* (0.98 ± 0.17 and 1.25 ± 0.2 folds, respectively). Therefore, the severity in defective ubiquitin homeostasis, represented by the increased levels of free ubiquitin chains and ubiquitinated substrates, correlates with increasing *leon* mutant strengths.10.7554/eLife.26886.004Figure 2.Defective ubiquitin homeostasis in *leon* mutants.(**A**) Western blot probed with ubiquitin (Ub) antibodies shows ubiquitin expression patterns in *w^1118^*, *19-2/19-2*, *leon^1^/19-2*, *leon^2^/19-2*, and postsynaptic expression of *UAS-leon* or *UAS-ED-leon* driven by *24B-GAL4* in *leon^1^/19-2*. α-Tub as control. (**B**) Images show FK2 (green) and HRP (red) immunostaining of NMJs in *w^1118^*, *leon^2^/19-2* and *leon^1^/19-2*, and postsynaptic expression of *UAS-leon* or *UAS-ED-leon* driven by *24B-GAL4* in *leon^1^/19-2*. The single FK2 images (right) are also shown. Arrowheads indicate synaptic regions. Scale bar, 10 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.004](10.7554/eLife.26886.004)

To further confirm disrupted ubiquitin homeostasis in *leon* mutants, the FK2 antibody that recognizes mono- and poly-ubiquitinated substrates, and free ubiquitin chains was used to immunostain dissected larval body walls. In wild-type controls, FK2 signals were detected at NMJs and in nuclei and Z-bands of muscles ([Figure 2B](#fig2){ref-type="fig"}). In *leon* mutants, overall FK2 signals were enhanced, and the enhancement was very prominent at the postsynaptic sites surrounding presynaptic boutons (indicated by arrowheads, [Figure 2B](#fig2){ref-type="fig"}). Consistent with Western blot analysis, the enhancement in the FK2 signal level was more pronounced in *leon^1^/19-2* than in *leon^2^/19-2* ([Figure 2B](#fig2){ref-type="fig"}).

We then examined the requirement of postsynaptic Leon and its deubiquitinating activity for ubiquitin homeostasis. In *leon^1^/19-2*, muscle expression of *UAS-leon*, but not *UAS-ED-leon*, by *24B-GAL4* suppressed the enhanced FK2 signals ([Figure 2B](#fig2){ref-type="fig"}). Western blot analysis showed that *24B-GAL4*-driven *UAS-leon* expression suppressed elevated free ubiquitin chains in *leon^1^/19-2* (0.49 ± 0.02 folds in comparison to *24B-GAL4, leon^1^/19-2*) and partially suppressed elevated ubiquitinated substrates (0.91 ± 0.04 folds). The partial suppression could be attributed to the limited muscle expression in the mutant. Interestingly, the expression of *UAS-ED-Leon* induced higher levels of free ubiquitin chains (2.17 ± 0.16 folds) and ubiquitinated substrates (2.19 ± 0.43 folds). It is possible that the enzymatic activity-deficient ED-Leon can associate with ubiquitin chains but cannot deubiquitinate them, and binding to ED-Leon sequesters ubiquitinated substrates from degradation. Taken together, these results indicate that Leon deubiquitinating activity is required for maintaining ubiquitin homeostasis in postsynapses.

Increases of postsynaptic proteins in *leon* mutants {#s2-3}
----------------------------------------------------

Aberrant NMJ morphology and postsynaptic ubiquitin homeostasis defects in *leon* mutants prompted us to examine constituents of synaptic organization. Several pre- and post-synaptic proteins were analyzed for their expression patterns and levels in *leon* mutants. Immunostaining for Dlg that is enriched in the SSR revealed a striking phenotype. In controls, SSR-localized Dlg exhibited thin circular rings in bouton sections. In *leon* mutants, Dlg-localized rings were expanded, showing much greater thickness and higher protein levels ([Figure 3A](#fig3){ref-type="fig"}). The thickness of Dlg-positive zones increased by 66% in *leon^2^/19-2* and by almost two folds in *leon^1^/19-2* in comparison to controls ([Figure 3C](#fig3){ref-type="fig"}, left panel). We further examined SSR-localized Cact and Dl expressions, which show Dlg-resembling ring patterns ([@bib22]). In *leon* mutants, circular Cact and Dl patterns were also expanded ([Figure 3A](#fig3){ref-type="fig"}). As Dlg, Cact and Dl present different aspects of postsynaptic functions, with Dlg promoting SSR formation, and Cact and Dl regulating GluRIIA abundance ([@bib3]; [@bib22]; [@bib28]), expansions of SSR-localized Dlg, Cact and Dl suggest that the SSR is also likely expanded in *leon* mutants.10.7554/eLife.26886.005Figure 3.Expansion of SSR- and PSD-localized proteins at *leon* NMJs.(**A**) Images show SSR-localized proteins Dlg, Cact and Dl in immunostaining of boutons in *w^1118^*, *leon^2^/19-2* and *leon^1^/19-2*. Co-staining of Dlg (green) and HRP (red) is shown (left panels). (**B**) Images show PSD-localized dPak, GluRIIA and GluRIIB immunostaining at synapses of *w^1118^*, *leon^2^/19-2* and *leon^1^/19-2*. Arrowheads indicate overlapping signals of expanded GluRIIA (green) and GluRIIB (red) clusters in middle panels. GluRIIA images are shown with magnification (right panels). (**C**) Bar graphs show means ± SEM of Dlg-positive zone thickness, dPak intensity and GluRIIA intensity and diameter in *w^1118^*, *leon^2^/19-2* and *leon^1^/19-2*. (**D**) Images show Dlg, dPak and GluRIIA immunostaining at NMJs, with postsynaptic *24B-GAL4-*driven *UAS-leon* or *UAS-ED-leon* expression in *leon^1^/19-2*. (**E**) Bar graphs show means ± SEM of Dlg-positive zone thickness, dPak intensity and GluRIIA intensity and diameter. All scale bars represent 5 μm except in magnified GluRIIA images, which is 1 μm. All data were compared to controls unless specifically indicated by brackets with n.s. indicating no significance, \*\* for p\<0.01 and \*\*\* for p\<0.001 according to Student's *t* tests. The detail statistic numbers also see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.005](10.7554/eLife.26886.005)10.7554/eLife.26886.006Figure 3---figure supplement 1.Localization of presynaptic proteins and expansion of GluRIIC clusters at *leon* NMJs.(**A**) Images show immunostaining for Brp (green) and dPak (red), and GluRIIC (right panels) at NMJs of *w^1118^*, *leon^2^/19-2* and *leon^1^/19-2*. Scale bar, 5 μm. (**B**) Bar graphs show means ± SEM of Brp density, GluRIIB intensity and GluRIIC intensity. All data were compared to controls with n.s. indicating no significance, \* for p\<0.05 and \*\*\* for p\<0.001 according to Student's *t* tests. The detail statistic numbers also see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. (**C**) Images show NMJ immunostaining for presynaptic proteins Synapsin (left), CSP and HRP (green and red, respectively, at middle), and Futsch and HRP (red and green, respectively, at right) in *w^1118^*, *leon^2^/19-2* and *leon^1^/19-2*. Scale bar, 5 μm (left) and 20 μm (right).**DOI:** [http://dx.doi.org/10.7554/eLife.26886.006](10.7554/eLife.26886.006)10.7554/eLife.26886.007Figure 3---figure supplement 2.Postsynaptic defects of *leon* mutants in earlier larval stages.(**A** and **B**) Images show Cact and GluRIIA immunostaining of NMJs in *w^1118^*, *leon^2^/19-2* and *leon^1^/19-2* at 72, 96 and 120 hr AEL. (**C**) Line graphs show means ± SEM of Cact-positive zone thickness and GluRIIA intensity and diameter at 72, 96 and 120 hr AEL. All data were compared to controls with \* for p\<0.05, \*\* for p\<0.01, \*\*\* for p\<0.001 according to Student's *t* tests. The detail statistic numbers also see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.007](10.7554/eLife.26886.007)10.7554/eLife.26886.008Figure 3---figure supplement 3.Presynaptic *leon* is not required for postsynaptic formation.(**A**) Images show immunostaining for Dlg (green, co-stained with HRP in red), dPak, and GluRIIA in presynaptic *D42-GAL4*-driven *UAS-leon* or *UAS-ED-leon* expression that failed to suppress Dlg, dPak and GluRIIA expansion in *leon^1^/19-2.* Scale bar, 5 μm. (**B**) Bar graphs show means ± SEM of Dlg-positive zone thickness, dPak intensity and GluRIIA intensity and diameter. No rescue effect was shown by n.s. (no significance) when compared to *D42-GAL4, leon^1^/19-2* according to Student's *t* tests. The detail statistic numbers also see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.008](10.7554/eLife.26886.008)10.7554/eLife.26886.009Figure 3---figure supplement 4.Postsynaptic *leon* knockdown exhibits postsynaptic defects.(**A**,**B**) Images show Dlg, dPak and GluRIIA immunostaining at NMJs. Expansions of Dlg, dPak, and GluRIIA were shown in *UAS-leonRNAi* driven by postsynaptic *24B-GAL4* (**A**), but not by presynaptic *D42-GAL4* (**B**). Scale bars, 5 μm. (**C**) Bar graphs show means ± SEM of Dlg-positive zone thickness, dPak intensity, GluRIIA intensity and diameter in *24B-GAL4*, *24B\>leonRNAi, D42-GAL4,* and *D42\>leonRNAi.* Pairwise comparisons are shown by brackets with n.s. indicating no significance and \* for p\<0.05, \*\* for p\<0.01, \*\*\* for p\<0.001 according to Student's *t* tests. The detail statistic numbers also see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.009](10.7554/eLife.26886.009)

At NMJs, each bouton contains multiple release sites paired with discrete receptor clusters that can be revealed by the localizations of presynaptic ELKS/CAST family protein Bruchpilot (Brp), and postsynaptic dPak ([@bib1]; [@bib26]; [@bib41]). Well-matched pairs of Brp and dPak were evenly distributed along the rim of and within bouton sections ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). In *leon* mutants, the size, spacing and density of Brp puncta appeared normal ([Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}). Strikingly, the postsynaptic dPak patches were enormously enlarged, and the spacing among them was often diminished, appearing as a continuous structure in bouton sections, particularly in *leon^1^/19-2* ([Figure 3B](#fig3){ref-type="fig"}). Quantification showed that the dPak levels were increased in *leon* postsynapses ([Figure 3C](#fig3){ref-type="fig"}). The normal one-to-one pairing between Brp and dPak could not be resolved in *leon* mutants because expanded and fused dPak patches could accommodate a few Brp puncta.

We further examined PSD-localized GluRs. GluRs are composed of four subunits, including essential subunits GluRIIC/GluRIII, GluRIID and GluRIIE and one of the two interchangeable subunits GluRIIA and GluRIIB ([@bib11]; [@bib30]). The GluRIIA and GluRIIB receptor clusters were distributed evenly in wild-type boutons. In *leon* mutants, GluRIIA and GluRIIB clusters were enlarged and overlapped, filling most of the space in bouton sections ([Figure 3B](#fig3){ref-type="fig"}, arrowheads). The wild-type GluRIIA cluster pattern, shown in the magnified image, was no longer present in *leon* mutants. Instead, GluRIIA clusters also appeared much like the dPak fusion pattern ([Figure 3B](#fig3){ref-type="fig"}, right panels). The average size of GluRIIA clusters was increased by 54% in *leon^2^/19-2%* and 89% in *leon^1^/19-2* ([Figure 3C](#fig3){ref-type="fig"}). The GluRIIC clusters were also enlarged in *leon* mutants ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Statistically, the intensities of GluRIIA, GluRIIB and GluRIIC immunostaining were all elevated in both *leon* mutants ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). These results indicate that the levels of postsynaptic SSR- and PSD-localized proteins are increased in *leon* mutants.

GluR clustering appears after axonal terminals innervate muscles in mid embryonic stages and SSR is formed in the first instar stage ([@bib18]; [@bib21]). The increases of SSR- and PSD-localized proteins in *leon* mutants could be a cumulative process from early larval stages. We compared expressions of SSR-localized Cact and PSD-localized GluRIIA in controls and *leon* mutants in the same stages. At *leon* NMJs, the thickness of Cact-positive zones and the intensity and size of GluRIIA clusters were larger than wild-type controls during 72 hr, 96 hr, and 120 hr AEL, with more severe defects in *leon^1^/19-2* than in *leon^2^/19-2* ([Figure 3---figure supplement 2A--C](#fig3s2){ref-type="fig"}). Therefore, the increases of SSR- and PSD-localized postsynaptic proteins in *leon* mutants are already prominent in early larval stages and progressively enhanced throughout later larval stages.

We then examined whether Leon deubiquitinating activity is required for proper postsynaptic growth. Expression of *UAS-leon* in muscles suppressed the expanded Dlg rings and the enlarged dPak and GluRIIA clusters in *leon^1^/19-2*. In contrast, enzyme-dead *UAS-ED-leon* failed to suppress these phenotypes ([Figure 3D--E](#fig3){ref-type="fig"}). Also, presynaptic expression of either *UAS-leon* or *UAS-ED-leon* had no effect on the increased size or intensity of the Dlg-positive zone, the dPak patch and the GluRIIA cluster in *leon* mutants ([Figure 3---figure supplement 3A--B](#fig3s3){ref-type="fig"}). To further confirm the requirement of postsynaptic *leon* for proper control of SSR- and PSD-localized protein levels, *leonRNAi* knockdown was performed in pre- or post-synaptic sites. When the *leonRNAi* transgene was driven by postsynaptic *24B-GAL4,* the Dlg-positive zone, the dPak patch, and the GluRIIA cluster were increased ([Figure 3---figure supplement 4A,C](#fig3s4){ref-type="fig"}). These phenotypes, however, were not detected by presynaptic knockdown in neurons ([Figure 3---figure supplement 4B,C](#fig3s4){ref-type="fig"}). Taken together, these analyses suggest that the deubiquitinating activity of Leon is required in postsynapses to control postsynaptic protein levels.

With the normal distribution, size and intensity of Brp puncta in *leon* mutants, we examined expression patterns of other presynaptic proteins. Immunostaining for synaptic vesicle-associated Synapsin and cysteine string protein (CSP) that display a pattern of small spreading puncta in boutons ([@bib16]), revealed no abnormality in *leon* mutants. The signals of microtubule-associated Futsch staining reach the terminal boutons in wild-type larvae, but stopped short without reaching terminals in *leon* mutants, suggesting a possible defect in the microtubule structure or stability in presynapses ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}).

Enlarged SSRs and synaptic membranes in *leon* mutants {#s2-4}
------------------------------------------------------

We further examined the ultrastructures of *leon* mutant boutons by transmission electron microscopy. Folded SSR surrounding boutons (colored in pink in [Figure 4A](#fig4){ref-type="fig"}), electron-dense membranes (within the pairs of red arrows in [Figure 4B](#fig4){ref-type="fig"}) and T-bars (indicated by blue arrows) were analyzed in *19-2/19-2* and *leon^1^/19-*2. In both mutants, SSR areas were expanded and membrane folds were tightly packed, resulting in compact membrane layers surrounding the sectioned bouton ([Figure 4A,A'](#fig4){ref-type="fig"}). While the bouton sizes in both *leon* mutants were comparable to controls, the SSR areas were dramatically increased by as much as two-fold ([Figure 4C](#fig4){ref-type="fig"}). Thus, the ultrastructural analysis confirms the expansion of SSR suggested by analyzing the SSR-localized Dlg, Cact and Dl in *leon* mutants ([Figure 3A](#fig3){ref-type="fig"}).10.7554/eLife.26886.010Figure 4.Ultrastructural analysis of *leon* mutant boutons showed enlarged SSR and longer synaptic membrane.(**A** and **A'**) Electron micrographs of type Ib boutons in *w^1118^*, *19-2/19-2* and *leon^1^/19-2*. The SSRs are colored in (**A**). Scale bars, 1 μm. (**B**) Electron-dense membranes with presynaptic T-bars, postsynaptic SSRs and vesicles are shown in *w^1118^*, *19-2/19-2* and *leon^1^/19-2*. Each pair of red arrowheads delineates the boundary of synaptic membranes, and arrows (blue) indicate T-bars. Scale bars, 0.2 μm. (**C**) Bar graphs show means ± SEM of bouton area, SSR area, synaptic length, T-bar/bouton and vesicles/bouton areas in *w^1118^*, *19-2/19-2* and *leon^1^/19-2*. All data were compared to *w^1118^* with n.s. indicating no significance and \*\*\* for p\<0.001 by Student's *t* tests. The detail statistic numbers also see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.010](10.7554/eLife.26886.010)

The electron-dense synaptic membranes along the bouton circumference were also prominently increased in *leon* mutants ([Figure 4B](#fig4){ref-type="fig"}). The average length of synaptic membranes was significantly increased in both *leon* mutants ([Figure 4C](#fig4){ref-type="fig"}). Therefore, synaptic membranes account for more than 60% of the bouton circumference in *leon* mutants, as compared to about 35% in controls. This phenotype is consistent with the enlargement of the PSD that is suggested by immunostaining of dPak and GluRs ([Figure 3B](#fig3){ref-type="fig"}). Presynaptically, the number of T-bars and vesicle numbers showed no significant difference to controls ([Figure 4C](#fig4){ref-type="fig"}). Thus, the ultrastructural analysis confirms the expansion of SSR and PSD in *leon* mutants.

Impaired electrophysiological properties at *leon* mutant NMJs {#s2-5}
--------------------------------------------------------------

We then examined the electrophysiological properties in *leon* mutants because of abnormal NMJ morphology in *leon* mutants. In both *19-2/19-2* and *leon^1^/19-2* mutants, the mEJC frequencies were comparable to the *+/19--2* control, showing no significant differences ([Figure 5A](#fig5){ref-type="fig"}). mEJC amplitudes in *19-2/19-2* and *leon^1^/19-2* were slightly larger than that in *+/19--2* control, although no statistical significance was detected (p=0.07 and p=0.13, respectively). Another independent mEJC amplitudes recording also suggested *leon^1^/19-2* had slightly larger mEJC amplitudes than *+/19--2* and *w^1118^* controls ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Interestingly, the EJC showed a dramatic reduction in *leon* mutants compared to the *+/19--2* control. The reduction in EJC leads to a reduction in the quantal content, determined by the ratio of the EJC amplitude to the mEJC amplitude ([Figure 5A](#fig5){ref-type="fig"}, bottom panels). Failure analysis also suggests that the quantal content was significantly reduced in the *leon^1^/19-2* mutant ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Both EJC amplitude and quantal content were restored by introducing *GFP-leon-GR* into *leon* mutants ([Figure 5A](#fig5){ref-type="fig"}).10.7554/eLife.26886.011Figure 5.Impaired electrophysiological properties at *leon* mutant NMJs.(**A**) Bar graphs compare frequency, mEJC amplitude, EJC amplitude, and quantal content in *19-2/19-2* and *leon^1^/19-2* to *+/19--2* control, and the rescue of *19-2/19-2* and *leon^1^/19-2* by *GFP-leon-GR*. (**B**) Bar graphs show that presynaptic *D42-GAL4*-driven Leon expression failed to restore both EJC amplitude and quantal content in *leon^1^/19-2* mutants. (**C**) Bar graphs show that *24B-GAL4-*driven muscular expression of *leon* partially restored EJC amplitude and quantal content in *leon^1^/19-2*. All data were compared to controls unless specifically indicated by brackets with n.s. indicating no significance, \* for p\<0.05, \*\* for p\<0.01 and \*\*\* for p\<0.001 by Student's *t* tests. The detail statistic numbers are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.011](10.7554/eLife.26886.011)10.7554/eLife.26886.012Figure 5---figure supplement 1.mEJC amplitude and failure analysis.(**A**) Bar graphs show that the mEJC amplitude in *leon^1^/19-2* mutant is slightly larger than *w^1118^* and *+/19--2* although no statistic significance was detected (see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). (**B**) Bar graphs show means ± SEM of quantal content in *w^1118^*, *+/19--2* and *leon^1^/19-2* by failure analysis. n.s. indicating no significance, \*\* for p\<0.01 and \*\*\* for p\<0.001 by Student's *t* tests. The detail statistic numbers are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.012](10.7554/eLife.26886.012)

We then examined whether Leon is required in pre- or post-synapses for restoring the EJC and quantal content in *leon^1^/19-2*. Presynaptic Leon expression by *D42-GAL4* failed to restore both EJC amplitude and quantal content in *leon* mutants ([Figure 5B](#fig5){ref-type="fig"}). Postsynaptic Leon expression by *24B-GAL4* partially restored the EJC amplitude and the quantal content in *leon^1^/19-2* ([Figure 5C](#fig5){ref-type="fig"}). The mEJC in *leon* mutants carrying *D42-GAL4* or *24B-GAL4* was significantly larger than that in respective GAL4 driver control, suggesting the mEJC increase in *leon* mutants might be sensitive to the variation in genetic backgrounds ([Figure 5B,C](#fig5){ref-type="fig"}). As postsynaptic expression of Leon also suppressed bouton reduction in the *leon* mutant, the reduction of the bouton and hence the total release sites in *leon* mutants could contribute partly to the electrophysiological defects. Indeed, there were about 20% reduction in the bouton number ([Figure 1A,B,E and F](#fig1){ref-type="fig"}), and about 15% reduction in the release sites at the *leon* mutant NMJ (Brp number per NMJ: *w^1118^*, 731.6 ± 31.6; *leon^2^/19-2*, 631.9 ± 28.1; *leon^1^/19-2*, 619.5 ± 31.1; n = 10 for all genotypes). With the 50% or more reduction in the EJC amplitude and the quantal content, other processes are also likely defective in the *leon* mutants.

Suppression of *leon* mutant phenotypes by reducing postsynaptic proteins {#s2-6}
-------------------------------------------------------------------------

Accumulations of postsynaptic proteins in the SSR or the PSD of *leon* mutants might cause some aspects of the mutant phenotypes. To test this idea, we examined whether reductions of the gene dosage for these postsynaptic proteins would alleviate *leon* mutant phenotypes. We first examined SSR-localized Dlg that is required for SSR formation ([@bib28]). Replacing the wild-type allele by the null *dlg^X1-2^* allele significantly suppressed the SSR-localized Cact expansion in *leon^1^/19-*2 ([Figure 6A,B](#fig6){ref-type="fig"}). However, the intensity and size of PSD-localized GluRIIA clusters was unaltered. Thus, this result suggests that the Dlg might mediate SSR but not PSD expansion in the *leon* mutant.10.7554/eLife.26886.013Figure 6.*leon* mutant phenotypes suppressed by reductions of gene dosages.(**A**) Immunostaining images show suppression of Cact expansion in *leon^1^/19-2* by *dlg^X1-2^,* and suppression of GluRIIA enlargement by *dpak^6^*, *pll^25^* and *dl^H^.* (**B**) Bar graphs show means ± SEM of Cact-positive zone thickness and GluRIIA intensity and diameter. (**C**) Immunostaining images of NMJs for Dlg and GluRIIA show suppression of GluRIIA enlargement in *cact^13^/+; leon^1^/19-2* as compared to *leon^1^/19-2.* (**D**) Bar graphs show means ± SEM of Dlg-positive zone thickness and GluRIIA intensity and diameter. Comparisons to *leon^1^/19-2* were assessed by Student's *t* tests with n.s. indicating no significance, \* for p\<0.05, \*\* for p\<0.01 and \*\*\* for p\<0.001. Scale bar, 5 μm. The detail statistic numbers are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. (**E**) Western blots show enhanced signals of Dlg, dPak and Cact in *leon^1^/19-2* in comparison to *w^1118^*. α-Tub as control.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.013](10.7554/eLife.26886.013)10.7554/eLife.26886.014Figure 6---figure supplement 1.*leon* mutant phenotypes suppressed by knockdown of postsynaptic proteins.(**A**) Examining expressions of *pll* in *da-GAL4*-driven *pllRNAi* by RT-PCR. The mRNA levels of *pll* decreased in *24B\>pllRNAi* as compared to GAL4 control. The mRNA expression of *Rpl19* serves as control. (**B**) Postsynaptic expression of mCD8GFP by *24B-GAL4* shows SSR enriched GFP signals with magnification on the right. Scale bars: left, 10 μm and right, 5 μm. (**C**) Immunostaining images of NMJs for GFP and GluRIIA show suppression of mCD8GFP-labeled SSR in *leon^1^/19-2* by RNAi transgenes for *dlg* and *dpak*, and suppression of GluRIIA enlargement by RNAi transgenes for *dpak*, *pll*, *dl-B* and *cact*. Scale bar, 5 μm. (**D**) Bar graphs show means ± SEM of GFP-positive zone thickness and GluRIIA intensity and diameter. Comparisons to *leon^1^/19-2* were assessed by Student's *t* tests with n.s. indicating no significance and \*\*\* for p\<0.001. The detail statistic numbers are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.014](10.7554/eLife.26886.014)

The PSD-localized dPak is required for GluRIIA cluster localization and SSR formation ([@bib1]). Replacing the wild-type copy of *dpak* by the null *dpak^6^* allele in *leon^1^/19-2* suppressed the GluRIIA cluster size and intensity. The Cact-positive zone, however, was not affected ([Figure 6A,B](#fig6){ref-type="fig"}). We also examined the SSR-localized complex of Pll, Dl and Cact that regulate GluRIIA abundance at the PSD ([@bib22]). Replacing the wild-type allele with respective *pll^25^*, *dl^H^*, or *cact^13^* in *leon^1^/19-2* suppressed the intensity and size of GluRIIA clusters but had no effect on the thickness of Cact- or Dlg-positive zones ([Figure 6A--D](#fig6){ref-type="fig"}). These results suggest that dPak and the Dl/Pll/Cact complex may mediate more specifically the expansion of GlRIIA clusters in the *leon* mutant.

To further confirm that reduced expressions of these postsynaptic proteins would suppress SSR or PSD enlargement, *dlgRNAi*, *dpakRNAi*, *dlRNAi*, *cactRNAi,* and *pllRNAi* that have been used previously ([@bib9]; [@bib36]; [@bib45]) or shown in this study ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) to effectively knockdown respective gene expression were introduced into *leon^1^/19-2*. To show the effect on the membranous SSR, muscle-expressed mCD8GFP that is enriched in the SSR membrane was used ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Expansion of mCD8GFP areas and enhancement of the signals were also detected in *leon^1^/19-2,* consistent with the increase of SSR ([Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}). Similarly, *dlg* knockdown suppressed mCD8GFP-enriched areas in *leon^1^/19-2*. However, the expanded PSD-localized GulRIIA clusters remained the same. Instead, *pll*, *dl* or *cact* knockdown suppressed the intensity and size of GluRIIA clusters in *leon^1^/19-2* but had no effect on the expanded mCD8GFP area ([Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}). Interestingly, *dpak* knockdown in *leon^1^/19-2* suppressed both mCD8GFP areas and GluRIIA clusters ([Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}), consistent with its role in the formation of both SSR and GluRIIA clusters ([@bib1]). Thus, these genetic suppressions support that accumulations of postsynaptic proteins at the SSR or PSD could mediate the expansion of postsynaptic specializations in *leon* mutants.

We then addressed whether the accumulations of postsynaptic proteins at the SSR or PSD are accompanied with increases in the total protein levels. Western blots for examining Dlg, dPak and Cact protein levels were performed in isolated body-wall muscles of wild-type and *leon* mutants. Quantification of the protein levels showed that Dlg, dPak and Cact were increased in *leon^1^/19-2* (1.19 ± 0.01, 1.3 ± 0.06, and 1.57 ± 0.28 folds, respectively), which were not significantly altered in *leon^2^/19-2* (0.97 ± 0.06, 0.93 ± 0.09, and 1.13 ± 0.13 folds, respectively). Thus, the increases in the protein levels, as well as other mechanisms, could contribute to postsynaptic accumulations of Dlg, dPak and Cact in *leon* mutants.

Suppression of *leon* mutant phenotypes by reducing Ubqn levels {#s2-7}
---------------------------------------------------------------

In *leon* mutants, ubiquitinated substrates accumulate ([Figure 2A](#fig2){ref-type="fig"}) while the enzymatic activities of the proteasome remain intact ([@bib42]), suggesting that ubiquitinated substrates fail to be transported for proteasomal degradation. We examined the involvement of the ubiquitin-like (UBL) and ubiquitin-association (UBA) domain proteins (UBL-UBA) that function as ubiquitin receptors to bind and shuttle ubiquitinated substrates to the proteasome for degradation. The *Drosophila* genome encodes three UBA-UBL ubiquitin receptors, Rad23, Ddi1 and Ubqn/Dsk2. We then tested whether any of the UBL-UBA proteins contribute to postsynaptic defects in *leon* mutants. RNAi transgenes for knocking down *Ubqn, Rad23* or *Ddi1* were effective in suppressing respective gene expression ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}), and were introduced into *leon* mutants to test their suppression of *leon* mutant phenotypes. Interestingly, postsynaptic *Ubqn* knockdown suppressed the size or intensity of Dlg-positive zones, dPak patches and GluRIIA clusters in both *leon^2^/19-2* and *leon^1^/19-2* ([Figure 7A,B](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1B,C](#fig7s1){ref-type="fig"}). In contrast, reductions in *Rad23* or *Ddi1* expression showed no obvious alteration of *leon* mutant phenotypes, except for a slight enhancement of Dlg-positive zones in *leon^2^/19-2* by *Rad23RNAi* ([Figure 7---figure supplement 1B,C](#fig7s1){ref-type="fig"}). These results suggest that Ubqn plays a prominent role in mediating postsynaptic phenotypes in *leon* mutants. We then investigated whether *Ubqn* knockdown has any effect on the defective ubiquitin homeostasis in *leon* mutant postsynapses. The FK2 immunostaining intensity, while increased in *leon* mutants, was dramatically reduced in muscles and synapses in *Ubqn* knockdown ([Figure 7A,B](#fig7){ref-type="fig"}). Therefore, the UBL-UBA protein Ubqn mediates ubiquitin homeostasis defects and postsynaptic defects in *leon* mutants.10.7554/eLife.26886.015Figure 7.Ubqn-dependent postsynaptic expansion and ubiquitin homeostasis defects in *leon* mutants.(**A**) Immunostaining images show suppression of Dlg, dPak and GluRIIA expansions, and reduction of FK2 intensity in *leon^1^/19-2* and *leon^2^/19-2* by *24B-GAL4*-driven postsynaptic expression of *UbqnRNAi\#1*. Scale bars: left, 5 μm, and right, 10 μm. (**B**) Bar graphs show means ± SEM of Dlg-positive zone thickness, dPak intensity, GluRIIA intensity and diameter, and FK2 intensities on synapses and muscles. (**C**) Western blot shows increases of Ubqn levels in *leon^2^/19-2* and *leon^1^/19-2* as compared to *w^1118^*. α-Tub as control. (**D**) Images show enhanced immunostaining signal of Ubqn (green, co-stained HRP in red) in *leon^2^/19-2* and *leon^1^/19-2* compared to *w^1118^*. The single Ubqn channel is also shown and yellow dashed lines delineate Cact-positive areas (Cact staining is not shown). Scale bars: left, 20 μm and right, 5 μm. Bar graphs show means ± SEM of Ubqn intensity at synaptic (left) or muscle (right) areas. All data were compared to controls unless specifically indicated by brackets with n.s. indicating no significance, \* for p\<0.05, \*\* for p\<0.01 and \*\*\* for p\<0.001 by Student's *t* tests. The detail statistic numbers are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.015](10.7554/eLife.26886.015)10.7554/eLife.26886.016Figure 7---figure supplement 1.Ubqn- but not Rad23- or Ddi1-dependent postsynaptic defects in *leon* mutants.(**A**) Examining expressions of *Ubqn*, *Rad23* and *Ddi1* in *da-GAL4*-driven *UbqnRNAi* (*\#1* and *\#2*), *Rad23RNAi* and *Ddi1RNAi* by RT-PCR. The mRNA levels of *Ubqn*, *Rad23* and *Ddi1* decreased as compared to GAL4 control. The mRNA expression of *Rpl19* serves as the control. (**B**) Immunostaining images show suppression of Dlg and GluRIIA expansion in *leon^2^/19-2* or *leon^1^/19-2* by *24B-GAL4-*driven *UbqnRNAi\#2* expression. However, the suppression was not detected by *24B-GAL4-*driven expression of *Rad23RNAi* and *Ddi1RNAi*. Scale bar, 5 μm. (**C**) Bar graphs show means ± SEM of Dlg-positive zone thickness and GluRIIA intensity and diameter. All data were compared to controls with n.s. indicating no significance, \* for p\<0.05, \*\* for p\<0.01 and \*\*\* for p\<0.001 according to Student's *t* tests. The detail statistic numbers are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.016](10.7554/eLife.26886.016)

Given the reduction in *Ubqn* suppressed *leon* mutant phenotypes, we examined whether Ubqn expression is altered in *leon* mutants. As expected, Ubqn protein levels on Western blots showed increases to more than two folds in both *leon* mutants ([Figure 7C](#fig7){ref-type="fig"}, *leon^2^/19-2*: 2.2 ± 0.54 folds and *leon^1^/19-2*: 2.03 ± 0.35 folds). Immunostaining for Ubqn revealed ubiquitous expression at NMJs and in muscles, with enrichment in nuclei ([Figure 7D](#fig7){ref-type="fig"}). In *leon* mutants, however, postsynaptic Ubqn immunostaining signals were highly elevated at the SSR (\>1.5 folds) and only weakly in other regions (1.2 folds in muscle). These results are consistent with that the increase in the Ubqn level in *leon* mutants could mediate expansions of Dlg-positive zones, dPak patches and GluRIIA clusters in *leon* mutants.

Ubqn induces and associates with ubiquitinated postsynaptic proteins {#s2-8}
--------------------------------------------------------------------

We then examined the role of Ubqn in postsynaptic development. The *Flag-Ubqn* transgene expressed by *24B-GAL4* in postsynapses caused expansions of Dlg-positive zones and GluRIIA clusters ([Figure 8A,B](#fig8){ref-type="fig"}), suggesting that elevated Ubqn levels could promote postsynaptic protein accumulation. However, Ubqn depletion by *UbqnRNAi* knockdown had no effect on these postsynaptic proteins ([Figure 8A,B](#fig8){ref-type="fig"}). As a ubiquitin receptor, Ubqn could associate with free ubiquitin chains, ubiquitinated substrates, or both in *leon* mutants. Immunoprecipitates of Flag-Ubqn probed by ubiquitin antibodies in Western blots displayed only smearing ubiquitin signals in high molecular weights, which were more prominent in *leon* mutants ([Figure 8C](#fig8){ref-type="fig"}, left panels). The ubiquitin signals represent Ubqn-associated, ubiquitinated substrates rather than ubiquitinated Ubqn, as SDS treatment of the Flag-Ubqn immunoprecipitates largely depleted the associated signals ([Figure 8C](#fig8){ref-type="fig"}, right panels). Taken together, these results indicate that Ubqn associates with ubiquitinated substrates but not free ubiquitin chains.10.7554/eLife.26886.017Figure 8.Ubqn promotes postsynaptic expansion and associates with ubiquitinated substrates.(**A**) Images show *24B-GAL4*-driven postsynaptic expression of *Flag-Ubqn* and *UbqnRNAi*, with immunostaining for Dlg or GluRIIA. Scale bar, 5 μm. (**B**) Bar graphs show means ± SEM of Dlg-positive zone thickness and GluRIIA intensity and diameter. All data were compared to *24B-GAL4* control with n.s. indicating no significance, and \*\*\* for p\<0.001 according to Student's *t* tests. The detail statistic numbers are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. (**C**) Western blots show input and immunoprecipitation of Flag-Ubqn from *24B-GAL4* control and *24B-GAL4*-driven *Flag-Ubqn* expression in wild type, *leon^2^/19-2* and *leon^1^/19-2.* The immunoprecipitates were probed with ubiquitin antibody. Left panels were performed in normal lysis buffer and right panels in lysis buffer containing SDS to disrupt protei association. Brackets indicate the smearing ubiquitin signals. α-Tub as control. (**D**) Western blots show input probed by Myc antibody (top panel) and immunoprecipitation of Myc-proteins probed by HA antibody. S2 cell transfected with plasmids for expressing HA-Ub and either Myc-dPak, Myc-Dlg, Myc-Cact, or Myc-GFP (lanes 1--4) or further co-transfected with Flag-Ubqn (lanes 5--8).**DOI:** [http://dx.doi.org/10.7554/eLife.26886.017](10.7554/eLife.26886.017)

We then tested whether elevation of Ubqn could associate and stabilize ubiquitinated postsynaptic proteins. Myc-tagged dPak, Dlg, Cact and GFP were separately co-transfected with HA-Ub into *Drosophila* S2 cells. Myc-immunoprecipitates probed by HA antibodies in Western blots displayed smearing signals ([Figure 8D](#fig8){ref-type="fig"}, lanes 1--4), indicating they are ubiquitinated proteins. Interestingly, upon further co-transfection of Flag-Ubqn, the Myc-precipitates present stronger ubiquitination signals, suggesting that Ubqn enhances ubiquitination of postsynaptic proteins ([Figure 8D](#fig8){ref-type="fig"}, lanes 5--8). Ubiquitination of GFP was also enhanced, indicating that Ubqn likely recognizes the conjugated ubiquitin chains for binding, rather than protein substrates. In summary, we propose that Ubqn is elevated in *leon* postsynaptic sites to bind and stabilize ubiquitinated proteins, a mechanism that could account for the accumulation of postsynaptic proteins in *leon* mutants.

Induction of *leon* mutant phenotypes by free ubiquitin chains {#s2-9}
--------------------------------------------------------------

In the absence of Leon deubiquitinating activity, free ubiquitin chains also accumulated in the postsynaptic area ([Figure 2C](#fig2){ref-type="fig"}). Thus, we tested whether free ubiquitin chains could induce phenotypes observed in *leon* mutants. To increase the level of free ubiquitin chains in vivo, the conserved C-terminal residues Gly75 and Gly76 that are essential for substrate conjugation were mutated to Ala. UbAA can be conjugated by the endogenous ubiquitin C-terminus onto the Lys48 residue, forming free ubiquitin chains, but is unable to conjugate onto substrates including endogenous ubiquitin due to the C-terminal mutations. Also, UbAA-induced free ubiquitin chains are resistant to Leon enzymatic activity as the C-terminal AA motif would prevent recognition by USP5 ([@bib7]). As controls, we also generated wild-type *UAS-HA-UbGG* that can conjugate to substrates, and *UAS-HA-UbAA-K48R* in which Lys48 was replaced by Arg, preventing ubiquitin chain formation on Lys48 of UbAA ([Figure 9A](#fig9){ref-type="fig"}). Larval lysates of *UAS-HA-UbGG*, *UAS-HA-UbAA* and *UAS-HA-UbAA-K48R* driven by *24B-GAL4* were probed with anti-HA antibodies in Western blot analyses ([Figure 9B](#fig9){ref-type="fig"}). As expected, UbGG produced smearing signals at higher-molecular weights, representing substrate-conjugated ubiquitin chains (lane 2). As expected, expression of UbAA formed ladders of free ubiquitin chains (lane 3). Finally, expression of UbAA-K48R failed to induce higher-molecular weight, smearing signals and free ubiquitin chains signals, except ubiquitin dimers, likely through conjugation of non-K48 residues (lane 4).10.7554/eLife.26886.018Figure 9.Postsynaptic defects induced by K48-linked free ubiquitin chains.(**A**) Diagram shows formation of K48-linked free ubiquitin chains between ectopically expressed UbGG or UbAA (yellow), and endogenous Ub (blue). UbAA-K48R, however, cannot form K48-linked free ubiquitin chains. The free ubiquitin chains initiated by ectopic UbGG, but not UbAA, could be deconjugated by Leon. In addition, UbGG also conjugates to substrates. (**B**) Western blot probed with HA antibody shows HA expression patterns in *24B-GAL4* control (lane 1), *24B\>HA-UbGG* (lane 2), *24B\>HA-UbAA* (lane 3) and *24B\>HA-UbAA-K48R* (lane 4). α-Tub as control. Arrow indicates ubiquitin monomer and arrowheads the dimer, trimer, tetramer and pentamer. (**C**) Images show *24B-GAL4*-driven postsynaptic expression of UbGG, UbAA and UbAA-K48R, with immunostaining for Dlg, dPak or GluRIIA. Scale bar, 5 μm. (**D**) Bar graphs show means ± SEM of Dlg-positive zone thickness, dPak intensity, GluRIIA intensity and diameter in *24B-GAL4-*driven expression of UbGG, UbAA and UbAA-K48R. (**E**) Bar graphs show means ± SEM of Dlg-positive zone thickness and GluRIIA intensity and diameter in *24B-GAL4*-driven UbAA expression in *leon^2^/19-2* or *leon^1^/19-2*. All data were compared to controls unless specifically indicated by brackets with n.s. indicating no significance, \* for p\<0.05, and \*\*\* for p\<0.001 according to Student's *t* tests. The detail statistic numbers are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.018](10.7554/eLife.26886.018)

To test which types of ubiquitins have impact on postsynaptic proteins, we performed immunostaining for Dlg, dPak and GluRIIA when these Ub transgenes were expressed in muscles. Quantitative analyses showed that postsynaptic expression of UbAA induced the expansion of Dlg-positive zones and GluRIIA clusters, and enhanced the intensity of dPak and GluRIIA clusters at postsynaptic sites ([Figure 9C,D](#fig9){ref-type="fig"}). These phenotypes, however, were not detected in expression of UbGG or UbAA-K48R. Given that UbAA, but not UbGG or UbAA-K48R, induced the formation of free ubiquitin chains ([Figure 9B](#fig9){ref-type="fig"}). Thus, these results are consistent with that K48-linked free ubiquitin chains induce higher-levels of postsynaptic proteins at postsynaptic sites.

However, UbAA overexpression failed to fully recapitulate the extreme severity of *leon* phenotypes, partly due to the difficulty of expressing high levels of free ubiquitin chains in vivo. To further correlate the level of free ubiquitin chains and the phenotypic severity, UbAA was overexpressed in *leon^2^/19-2* and *leon^1^/19-2* in which lower or higher levels of free ubiquitin chains accumulated ([Figure 2A](#fig2){ref-type="fig"}). Quantification of Dlg-positive zones and GluRIIA cluster intensity and size indicated that overexpression of UbAA further enhanced the hypomorphic *leon^2^/19-2* phenotypes, but was unable to exacerbate *leon^1^/19-2* defects ([Figure 9E](#fig9){ref-type="fig"}). These analyses suggest that the amounts of free ubiquitin chains correlate to the protein levels at postsynaptic sites.

Recapitulation of *leon* mutant phenotypes by coexpression of free ubiquitin chains and Ubqn {#s2-10}
--------------------------------------------------------------------------------------------

Both levels of free ubiquitin chains and Ubqn were highly elevated in *leon* mutants. Also, when overexpressed, both were able to induce protein accumulation at postsynaptic sites. We then investigated the relationship between free ubiquitin chains and Ubqn in these processes. Postsynaptic expression of UbAA, but not UbGG or UbAA-K48R, slightly induced the Ubqn levels, including synaptic sites and muscles ([Figure 10A,B](#fig10){ref-type="fig"}). Conversely, overexpression of Ubqn could not induce free ubiquitin chains ([Figure 10C](#fig10){ref-type="fig"}). As UbAA only induced mild postsynaptic phenotypes accompanying with slight Ubqn elevation, we therefore tested whether co-expression of UbAA and Ubqn could further enhance these phenotypes. This experiment was performed in a *leon* heterozygous background, *+/19--2,* in which postsynapses are normal but more sensitive to the induction of phenotypes. Expression of either UbAA or Ubqn in the sensitive background induced mild enhancement of FK2 intensity in postsynaptic sites. However, combined overexpression of UbAA and Ubqn in the same background caused a large increase in FK2 immunostaining intensity ([Figure 10D,E](#fig10){ref-type="fig"}). This co-expression also resulted in larger expansion of Cact-positive zones and GluRIIA clusters than expression of either one alone ([Figure 10D,E](#fig10){ref-type="fig"}). Thus, these data suggest that Ubqn and free ubiquitin chains in *leon* mutants could function together to induce defective ubiquitin homeostasis, and protein accumulations at the postsynaptic site.10.7554/eLife.26886.019Figure 10.Free ubiquitin chains induce Ubqn levels and enhance postsynaptic defects when co-expressed with Ubqn.(**A**) Immunostaining images show NMJs for Ubqn (green) and HRP (red) in *24B-GAL4*-driven postsynaptic expression of UbGG, UbAA and UbAA-K48R. The single Ubqn channel is also shown and yellow dashed lines delineate HRP-positive areas. Scale bars: left, 20 μm and right, 5 μm. (**B**) Bar graphs show means ± SEM of synaptic and muscular Ubqn intensities when UbGG, UbAA or UbAA-K48R was expressed by *24B-GAL4*. (**C**) Western blot probed with Ub antibody shows ubiquitin expression patterns in *24B-GAL4* control and *24B\>Flag-Ubqn*. α-Tub as control. (**D**) Images show NMJ immunostaining for FK2 (green, co-stained with HRP in red), Cact or GluRIIA in expression of *HA-UbAA*, *Flag-Ubqn,* or both in *+/19--2* background. Scale bars: left, 20 μm and right, 5 μm. (**E**) Bar graphs show means ± SEM of synaptic FK2 intensity, Cact-positive zone thickness and GluRIIA intensity and diameter. All data were compared to controls unless specifically indicated by brackets with n.s. indicating no significance, \* for p\<0.05, \*\* for p\<0.01, and \*\*\* for p\<0.001 by Student's *t* tests. The detail statistic numbers are in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.019](10.7554/eLife.26886.019)

Discussion {#s3}
==========

At NMJs, postsynaptic SSR membranes are highly convoluted, showing many layers of folded membranes that surround presynaptic boutons. Each bouton contains multiple release sites where neurotransmitters are released from synaptic vesicles and received by receptors localized at the PSD ([@bib2]; [@bib6]). Leon negatively regulates these unique postsynaptic specializations through control of postsynaptic protein levels. The Leon function in postsynapses is specific as presynaptic defects were not obvious, and *leon* mutant defects could be rescued mostly by postsynaptic Leon expression. Leon tightly controls postsynaptic specializations throughout larval development. As such dramatic and concomitant expansion of SSRs and PSDs is rarely detected in other reported mutants, our study suggests that Leon likely executes a coordinated program in confining postsynaptic specializations.

The requirement of Leon deubiquitinating activity indicates that Leon functions as a conserved member of the USP5 family to disassemble free ubiquitin chains, thereby maintaining ubiquitin homeostasis in vivo. In *leon* mutants, accumulations of free ubiquitin chains and ubiquitinated substrates were detected ([Figure 2A](#fig2){ref-type="fig"}). The immunostaining signals by FK2 antibodies were also highly intensified, in particular, at the postsynaptic site ([Figure 2B](#fig2){ref-type="fig"}). Thus, free ubiquitin chains and ubiquitinated substrates are two major targets that are suppressed by USP5/Leon activity in postsynapses. Postsynaptic expression of UbAA that forms free ubiquitin chains mildly enhanced FK2 intensity and induced higher-levels of SSR- and PSD-localized proteins, similar to but not as dramatic as what was observed in *leon* mutants. In addition to free ubiquitin chains, ubiquitinated substrates also contribute to SSR and PSD expansion. In *leon* mutants, accumulation of ubiquitinated substrates could be attributed to disruption of proteasomal degradation, although the enzymatic activity of the proteasome remains active ([@bib42]). We therefore hypothesized that the delivery of ubiquitinated substrates to proteasomal degradation is hindered, leading to their accumulation. In supporting of this idea, we showed that reducing the level of the UBA-UBL ubiquitin shuttling protein Ubqn could suppress SSR- and PSD-localized protein levels in *leon* mutants. Overexpression of Ubqn also caused accumulations of ubiquitinated substrates in postsynapses. The Ubqn protein itself also accumulated at the SSR region, and bound ubiquitinated substrates. Thus, in *leon* mutant postsynapses, higher levels of Ubqn could stall proteasomal degradation and cause accumulation of ubiquitinated substrates in postsynapses ([Figure 11](#fig11){ref-type="fig"}). Taken together, we propose that accumulated free ubiquitin chains and Ubqn-bound ubiquitinated substrates are two primary causes of *leon* mutant defects.10.7554/eLife.26886.020Figure 11.Model for Leon in maintaining postsynaptic ubiquitin homeostasis and protein degradation.Schematics show postsynaptic distributions of free and substrate-conjugated ubiquitin chains in wild-type (upper left) and *leon* mutant (upper right) postsynaptic sites. (bottom) The proposed pathway for Leon/Usp5 in postsynapses: Leon downregulates the levels of free ubiquitin chains through the deubiquitinating activity. Accumulation of free ubiquitin chains promotes Ubqn elevation, and Leon may suppress Ubqn levels through alternative pathways (dotted lines). Accumulated Ubqn could bind and stabilize ubiquitinated substrates. However, free ubiquitin chains and Ubqn when both are increased, collaborate to induce more accumulations of ubiquitinated substrates. Finally, accumulated substrates contribute to postsynaptic protein accumulation and SSR and PSD expansions (Solid lines: supported by experiments in this study; dash lines: proposed links).**DOI:** [http://dx.doi.org/10.7554/eLife.26886.020](10.7554/eLife.26886.020)

Interestingly, Ubqn level was also upregulated in UbAA overexpression. Conversely, free ubiquitin chains maintained constant levels when Ubqn was overexpressed. These experiments would suggest that accumulation of free ubiquitin chains directly induces higher levels of Ubqn in *leon* mutants, which could be mediated through stabilization of Ubqn or other pathways. The effect of postsynaptic overexpression of UbAA or Ubqn only induced partial *leon* mutant phenotypes, such as in the levels of FK2 and postsynaptic proteins, implying tight control on ubiquitin homeostasis and protein substrate levels. Co-overexpression of UbAA and Ubqn together induced much higher FK2 intensity, and higher postsynaptic protein levels than overexpression of either one alone. Thus, Ubqn and UbAA are unlikely to function in a simple linear pathway, as the overexpression of UbAA would have suggested. Other factors such as ubiquitinated substrates have to be taken into account for the full expressivity of *leon* mutant phenotypes.

With the dramatic expansions of SSR and PSD in *leon* mutants, we assumed many postsynaptic proteins would be elevated in *leon* postsynapses. By examining some representative proteins, we showed that those proteins contribute to *leon* postsynaptic expansions. The SSR-localized Dlg was elevated and its reduction specifically alleviated SSR expansion. PSD-localized dPak was highly elevated near postsynaptic membranes, and dPak accumulation contributes SSR and PSD expansion in *leon* mutants. Two of SSR-localized NF-κB complex, Cact and Dl, were found to accumulate in *leon* mutant SSR. Eliminating one wild-type allele or RNAi knockdown of *cact*, *dl,* or *pll* in *leon* mutants also suppressed the enlargement of GluRIIA clusters, consistent with their roles in regulating GluRIIA cluster abundance. As dramatic increases of protein levels were not detected in Western blots for *leon* mutants, as would be expected from immunostaining of postsynaptic proteins, other mechanisms like subcellular recruitment to postsynapses could be also involved.

How these postsynaptic proteins accumulated at *leon* mutant postsynapses? Ubqn could be the key factor in this process. Ubqn associated with ubiquitinated substrates in *leon* mutants, and could stabilize ubiquitinated dPak, Dlg and Cact ([Figure 8D](#fig8){ref-type="fig"}). These results suggest that Ubqn could associate with and stabilize ubiquitinated postsynaptic proteins, which contribute to *leon* mutant phenotypes. In particular, Ubqn localized at postsynaptic sites and was enriched locally when *leon* was inactivated, providing the specificity of Leon regulation to postsynaptic specializations ([Figure 11](#fig11){ref-type="fig"}). Interestingly, while reduction of Ubqn suppressed SSR- and PSD-localized protein levels in *leon* mutants, it enhanced *leon* mutant lethality, indicating the distinct role of Ubqn in postsynapses. Our current model suggests sequential events in *leon* mutant postsynapses, in which elevated free ubiquitin chains induced Ubqn upregulation, Ubqn further stabilized postsynaptic proteins, and accumulated postsynaptic proteins promote SSR and PSD expansion ([Figure 11](#fig11){ref-type="fig"}). The inability to fully recapitulate *leon* mutant phenotypes could be due to limitation in overexpression or involvement of other factors. Thus, Leon maintains ubiquitin homeostasis through regulation of free ubiquitin chains, Ubqn levels and ubiquitinated substrates for proper development of postsynaptic specializations.

Our model that hinges on postsynaptic Ubqn has resemblances to the pathogenesis of ubiquilin 2-associated ALS ([@bib8]; [@bib14]). Ubiquitin and ubiquilin 2 accumulations are common features in ALS patients, reminiscent of Ubqn and free ubiquitin chain accumulations in *leon* mutants. In addition to ubiquitin homeostatic imbalance and postsynaptic differentiation in *leon* mutants, overexpression of Ubqn causes pupal lethality and modifies TDP-43 toxicity in an ALS model ([@bib20]; [@bib29]). Whether ubiquilin 2 accumulation could recruit free ubiquitin chains or ubiquitinated substrates to ubiquitin inclusions and enhance disease progression will be pivotal to understand the pathological mechanisms. Thus, Leon/USP5 holds Ubqn in check and prevents ubiquitin homeostatic imbalance, making *USP5* as a potential candidate disease gene in ubiquitin homeostasis-related diseases.

Materials and methods {#s4}
=====================

Fly stocks {#s4-1}
----------

*leon^1^*, *leon^2^*, *19--2* mutant alleles, *UAS-Flag-leon* and *UAS-Flag-ED-leon* are described in our previous study ([@bib42]). All flies were reared at 25°C.*GFP-leon-GR* was constructed by fusing *GFP* to the ATG codon of *leon* cDNA driven by the genomic sequence between *BtbVII* ATG and *leon* ATG. Transgenic flies carrying *UAS-HA-UbGG, UAS-HA-UbAA*, *UAS-HA-UbAA-K48R* and *UAS-Flag-Ubqn* were generated in this study. *dlg^X1-2^* ([@bib44]), *dl^H^*, *cact^13^*and *pll^25^* ([@bib22]) and *UAS-UbqnRNAi\#2* ([@bib17]) have been described in respective studies. *24B-GAL4* (RRID:[BDSC_1767](https://scicrunch.org/resolver/BDSC_1767)), *D42-GAL4* (RRID:[BDSC_8816](https://scicrunch.org/resolver/BDSC_8816)), *da-GAL4* (RRID:[BDSC_55851](https://scicrunch.org/resolver/BDSC_55851)), *UAS-mCD8GFP* (RRID:[BDSC_5137](https://scicrunch.org/resolver/BDSC_5137)) and *dpak^6^* (RRID:[BDSC_8809](https://scicrunch.org/resolver/BDSC_8809)) were obtained from Bloomington Drosophila Stock Center, Bloomington, IN. *UAS-leonRNAi* (ID 17567), *UAS-UbqnRNAi\#1* (ID 47447), *UAS-Rad23RNAi* (ID 30497), *UAS-Ddi1RNAi* (ID 40512), *UAS-pllRNAi* (ID 103774), *UAS-dlgRNAi* (ID 41136) and *UAS-dpakRNAi* (ID 108937) were from Vienna *Drosophila* Resource Center, Austria. *UAS-cactRNAi* (5848 R-3) was from NIG-FLY, Japan. *UAS-dl-BRNAi* was from Steven A. Wasserman ([@bib45]).

Immunostaining {#s4-2}
--------------

NMJ 6/7 phenotypes were analyzed at the A3 segment of late third instar larvae as previously described ([@bib37], [@bib38]). Larvae were dissected in cold calcium free HL3 saline (70 mM NaCl, 5 mM KCl, 20 mM MgCl~2~, 10 mM NaHCO~3~, 5 mM trehalose, 115 mM sucrose, and 5 mM HEPES, pH 7.2) and larval body fillets were fixed in 4% paraformaldehyde for 20 min and washed in PBT (0.01% triton-X-100) for 15 min three times. Fixed fillets were incubated with primary antibodies overnight at 4°C, rinsed in PBT three times, and incubated with secondary antibodies for 2 hr at room temperature. Primary antibodies: mouse anti-Dlg (4F3, 1:100; Developmental Studies Hybridoma Bank, DSHB, Iowa City, IA; RRID:[AB_528203](https://scicrunch.org/resolver/AB_528203)), mouse anti-Brp (nc82, 1:100; DSHB; RRID:[AB_2314868](https://scicrunch.org/resolver/AB_2314868)), mouse anti-Synapsin (3C11/SYNORF1, 1:50; DSHB; RRID:[AB_528479](https://scicrunch.org/resolver/AB_528479)), mouse anti-CSP (ab49, 1:100; DSHB; RRID:[AB_2307345](https://scicrunch.org/resolver/AB_2307345)), mouse anti-Futsch (22C10, 1:200; DSHB; RRID:[AB_528403](https://scicrunch.org/resolver/AB_528403)), rabbit anti-Cact (1:500; RRID:[AB_2314056](https://scicrunch.org/resolver/AB_2314056); \[[@bib32]\]), rabbit anti-Dl rabbit (1:500; RRID:[AB_2570310](https://scicrunch.org/resolver/AB_2570310)), anti-dPak (1:1000; RRID:[AB_2567913](https://scicrunch.org/resolver/AB_2567913); \[[@bib40]\]), rabbit anti-GluRIIB (1:1000; RRID:[AB_2568753](https://scicrunch.org/resolver/AB_2568753); \[[@bib30]\]), rabbit anti-GluRIIC (1:2500; RRID:[AB_2568754](https://scicrunch.org/resolver/AB_2568754); \[[@bib30]\]), mouse anti-FK2 (1:500; RRID:[AB_10541840](https://scicrunch.org/resolver/AB_10541840); Enzo Life Sciences, Farmingdale, NY.) chicken anti-GFP (1:500; RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798); Abcam, UK.), mouse anti-UBQLN2 (1:100; RRID:[AB_565683](https://scicrunch.org/resolver/AB_565683); Abnova, Taiwan), goat anti-HRP conjugated FITC, rabbit anti-HRP conjugated TRITC or Cy5 (RRID:[AB_2314647](https://scicrunch.org/resolver/AB_2314647); RRID:[AB_2340257](https://scicrunch.org/resolver/AB_2340257); Jackson ImmunoResearch, West Grove, PA) and mouse anti-Leon (1:100) generated against GST-Leon fusion protein (LTK BioLaboratories, Taiwan). Muscles were visualized by FITC-conjugated phalloidin (1:2000; Sigma-Aldrich, St. Louis, Mo), which are not shown in figures. For GluRIIA (mouse, 1:100, RRID:[AB_528269](https://scicrunch.org/resolver/AB_528269); DSHB) immunocytochemistry, larval fillets were fixed in Bouins fixative (Sigma-Aldrich.) for 5 min, followed by the protocol described above. Larval fillets were mounted onto slides with PBS containing 87.5% glycerol and 0.22M 1, 4-diaza-byciclo (2.2.2) octane (Dabco, Sigma-Aldrich.). NMJ images were acquired by confocal Z-stack scanning (Zeiss LSM510, Germany) using 40x water and 100x oil objectives and processed by LSM 5 image examiner and Adobe Photoshop.

Western blots, Immunoprecipitation and S2 cell transfection {#s4-3}
-----------------------------------------------------------

Third instar larva fillets were homogenized in lysis buffer (150 mM NaCl, 5 mM EDTA, 0.5% Triton-X-100, 1% NP-40 and 50 mM Tris-HCl, pH, 7.4) supplemented with protease inhibitor cocktails (Roche, Swiss), 1 mM PMSF, 1 mM DTT and 2 mM Na~3~VO~4~ and separated in Nupage 4% \~ 12% Bis-Tris gel (Thermo Fisher Scientific, Waltham, MA) for Western blots. For immunoprecipitation, larvae were lysed in lysis buffer or lysis buffer with 0.5% SDS. Lysates with 0.5% SDS buffer were further diluted to final 0.2% SDS for immunoprecipitation. Lysates after incubation with Flag M2 beads (AB_2637089; Sigma-Aldrich) overnight were washed by lysis buffer three times and separated in Nupage 4% \~ 12% Bis-Tris gel for Western blots. *Drosophila* S2 cell line was purchased from Invitrogen (RRID:[CVCL_Z232](https://scicrunch.org/resolver/CVCL_Z232); Invitrogen, Thermo Fisher Scientific) and *Drosophila* S2 cells were cultured at 25°C in Schneider's *Drosophila* medium with 10% heat-inactivated fetal bovine serum (Gibco, Thermo Fisher Scientific). S2 cells were transfected with plasmids by Effectene Transfection Reagent (QIAGEN, Germany). Plasmids include *Ub-GAL4, Myc-dPak, Myc-Dlg, Myc-Cact, Myc-GFP, Flag-Ubqn,* and *HA-Ub*. After 72 hr transfection, S2 cells were lysed in lysis buffer for immunoprecipitation by Myc agarose beads (9E10; Santa Cruz Biotechnology, Dallas, TX). Immunoprecipitated lysates were washed by lysis buffer three times and separated in 8% acrylamide gels. Antibodies against Dlg (1:1000), dPak (1:5000), Cact (1:5000), ubiquitin (P4D1, 1:1000; RRID; AB_628423; Santa Cruz Biotechnology), mouse anti-UBQLN2 (1:100; Abnova), α-Tubulin (1:10000; Sigma-Aldrich), anti-Myc (9E10, 1:1000; RRID:[AB_627268](https://scicrunch.org/resolver/AB_627268); Santa Cruz Biotechnology) and HA-HRP (1:2000; Sigma-Aldrich) were used in Western blots.

Electron microscopy {#s4-4}
-------------------

Processing and analysis of ultrastructures of synaptic boutons by electron microscope were as described previously ([@bib38]), with some modification. Larval fillets were dissected in cold calcium-free HL3 saline and fixed in modified Trump's fixative (4% paraformaldehyde/1% glutaraldehyde/0.1 M sodium cacodylate buffer, pH 7.2) and postfixed with 1% aqueous osmium tetroxide/0.1M sodium cacodylate buffer (pH7.2). The dissected muscles 6/7 of A3 segments were stained with 2% uranyl acetate, dehydrated in a graded ethanol series and infiltrated with graded Spurr's series in a microwave (PELCO BioWave Laboratory Microwave System, Ted Pella, Redding, CA). Thin sections (100 nm) were sectioned by ultramicrotome (Leica, Germany.) and further stained with uranyl acetate and lead citrate. Images were acquired by Tecnai G2 Spirit TWIN (FEI Co, Hillsboro, OR.) and a Gatan CCD Camera (794.10 .BP2 MultiScan). TEM data were quantified by MetaMorph V6.3r7 (Molecular Devices, Sunnyvale, CA).

Quantifications {#s4-5}
---------------

The thickness of Dlg-, Cact-, or mCD8GFP-positive zone was analyzed in the original confocal Z-stack images and averaged for lengths across the zone defined by eight straight lines radiating from the bouton center. GluRIIA cluster diameters were analyzed in the original confocal Z-stack images, which were scanned with 0.5 μm intervals and covered overall boutons. Isolated GluRIIA cluster with circular shapes in different Z sections were selected to avoid choosing super-imposed ones for scoring their diameters. When elliptic cluster were chosen, the long and short diameters were averaged to reach the average diameters. Brp number and HRP-labeled NMJ areas were analyzed in the original confocal Z-stack images and Brp density was the ratio of Brp number to HRP-labeled NMJ area. Branch length was calculated from HRP labeling. GluRIIA/IIB/IIC and dPak intensities were the summation from all pixels of NMJs, which was normalized to the total HRP intensity at NMJs by Image J. Synaptic FK2 and Ubqn intensities were calculated by mean pixels in the synaptic area normalized to mean HRP pixels in the synaptic area by Image J. Muscular FK2 and Ubqn intensities were averaged from mean pixels of four muscle areas and normalized to mean HRP pixels in the postsynaptic sites by Image J. The intensities were normalized again to the control genotype for presentation in bar graphs.

To estimate expression levels from Western blots, each set of experiments was performed three times independently, and intensities for bands or areas of interest were processed by Image J with normalization to the internal control α-Tub. The areas of interest for mono-ubiquitin, free ubiquitin chains and ubiquitinated substrates are indicated in [Figure 2A](#fig2){ref-type="fig"}.

RT-PCR {#s4-6}
------

Larvae for knockdowns of *UAS-UbqnRNAi* (*\#1* and *\#2*), *UAS-Rad23RNAi*, *UAS-Ddi1RNAi*, *UAS-SyndRNAi* and *UAS-pllRNAi* driven by *da-GAL4* were reared at 25°C. mRNA of indicated genotypes was extracted from third-instar larvae by RNAzol RT (Molecular Research Center, Cincinnati, OH), followed by the reverse transcription of cDNAs by ImProm-II Reverse Transcription System through oligo-dT (Promega, Madison, WI). The mRNA expressions were amplified by PCR using *Ubqn*, *Rad23*, *Ddi1*, *pll* and *Rpl19* specific primers.

Electrophysiological recordings {#s4-7}
-------------------------------

For sample preparation, larvae were dissected with the segmental nerve cut near the ventral ganglion in cold modified Ca^2+^-free HL3.1 saline (70 mM NaCl, 5 mM KCl, 10 mM MgCl~2~, 10 mM NaHCO~3~, 5 mM trehalose, 115 mM sucrose, 5 mM HEPES, pH 7.2). Preparations were then incubated in modified HL3.1 saline containing 0.6 mM CaCl~2~ for stimulation, and recordings were taken at room temperature. The two-electrode voltage-clamp was filled with 3 M KCl and impaled in muscle 6 of the A3 segment. One microelectrode (15 \~ 20 MΩ) monitored the muscle membrane potential while the other (5 \~ 8 MΩ) passed electric currents. The muscle membrane potential was clamped at a command value of −60 mV. mEJCs occurring in the background within 100 s were obtained without any stimulation on the segmental nerve. To record an EJC, the segmental nerve was stimulated every 10 s from the cut end that was connected by a suction electrode with 0.1 msec of pulse duration at the voltage two times that of the threshold. Signals were digitized at 50 kHz by a DigiData 1440 interface (Molecular Devices), low-pass filtered at 10 kHz, and saved on an IBM-compatible PC for analysis. For failure analysis, EJC was evoked in 0.2 mM \[Ca^2+^\], and the failure rate was calculated by ln(n/N), with n the number of failure events, and N the total number of stimuli.
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Thank you for choosing to send your work, \"USP5/Leon deubiquitinase confines postsynaptic differentiation by maintaining ubiquitin homeostasis through Ubiquilin\", for consideration at *eLife*. Your article has been reviewed by K VijayRaghavan as Senior editor and three reviewers, one of whom, Hugo Bellen, is a member of the Board of Reviewing Editors. Although the work is of interest, we regret to inform you that the findings at this stage are too preliminary for further consideration at *eLife*. However, we are willing to entertain a resubmission that addresses the reviewers' comments.

We think that the mechanistic angle including the interpretation of the electrophysiological phenotype will be hard to fix within two months. However, we believe that you should be able to revise the manuscript in a satisfying manner and it should then hopefully be a candidate for *eLife*. We would be happy to re-review such a thoroughly revised version.

*Reviewer \#1:*

In the current manuscript, Wang et al. assess the function of the deubiquitinase Leon during *Drosophila* neuromuscular junction (NMJ) development and document that it controls proper postsynaptic differentiation. Leon is the homolog of USP5, a deubiquitinase that functions specifically to disassemble free, substrate-unconjugated polyubiquitin chains to replenish the pool of mono-ubiquitin. Previously, the same group described that loss of *Drosophila* leon is lethal and leads to the accumulation of both free poly-ubiquitin chains, as well as polyubiquitinated proteins. In the current study, the authors describe a role for leon in regulating ubiquitin homeostasis and restricting the growth and development of the postsynaptic density (PSD) and subsynaptic reticulum (SSR): whereas presynaptic components are unaffected, the levels of numerous postsynaptic components (Dlg, GluRIIA/B, dPak, Cact and Dl) are strongly increased. Surprisingly, the observed phenotypes can be significantly rescued by reducing the levels of Ubiquilin, a protein that transports ubiquitinated substrates to the proteasome. In addition, *leon* mutants display increased Ubiquilin levels in *leon* mutants and overexpressing ubiquilin in a wildtype background mimics the phenotypes found in *leon* mutants, albeit to a lesser extent. These data argue for a role of Ubiquilin in mediating PSD and SSR growth. However, free polyubiquitin chains seem to also play a role as overexpressing these chains also shows a milder version of the phenotypes observed in *leon* mutants. Finally, combined overexpression of Ubiquilin and free ubiquitin chains in a wildtype background completely mimics *leon* mutants. Hence, based on the presented data, Leon appears to restrict postsynaptic development by regulating the levels of both Ubiquilin and free polyubiquitin chains.

This is a carefully executed, well-controlled study that consists of an extensive and detailed phenotypic characterization of *leon* mutants. The figures are nicely organized and in most cases very convincingly bring the message across. It is counterintuitive that reducing the levels of a protein that removes polyubiquitinated proteins in a background in which the levels of polyubiquitinated substrates are elevated. However, the genetic experiments that were performed are clean and clearly show that free polyubiquitin chains, in combination with elevated Ubiquilin levels can affect postsynaptic development. How this occurs remains elusive and is not well discussed by the authors. The experiments to tease out the details of the actual mechanism underlying NMJ overgrowth in *leon* mutants are not trivial and may represent a continuation / expansion on this paper. I enjoyed reading this paper and would like to recommend it for publication in *eLife*, if the authors can expand / hypothesize on the consequences of free ubiquitin chains / elevated Ubiquilin levels in the muscle.

Major comment:

-- My major comment is a lack of interpretation of the results in the Discussion. At the moment, the Discussion mostly recapitulates the data. How do the authors think Ubiquilin and free ubiquitin chains affect NMJ development?

As the levels of Dlg, Cac, etc are elevated at the earliest stages of NMJ development, it appears that either (a) the activity and/or levels of the master regulator of postsynaptic density formation, which remains unknown, are increased in *leon* mutants or (b) that the individual proteins that are found at the PSD and SSR are directly regulated by Ubiquilin and/or free ubiquitin chains. This is not discussed at the moment, but is essential for the reader to help interpret the consequences of these findings.

How could free ubiquitin chains alter protein levels / activity? Does overexpressing free ubiquitin chains lead to a similar increase in Ubiquilin levels or are these two events independent?

In addition, is the increase in Ubiquilin due to a lack of free ubiquitin monomers? For instance, if the authors overexpress ubiquitin in *leon* mutants, can this rescue the increase in Ubiquilin levels? Does this affect NMJ development?

*Reviewer \#2:*

The manuscript reports a very pronounced synaptic phenotype for mutations in Leon, the fly homolog of USP5. Studying the neuromuscular junction, they provide strong evidence that there is an extreme expansion of the folds of the subsynaptic reticulum and a concomittent increase in the postsynaptic presence of proteins associated with that structure. In addition, they show that some proteins found in the postsynaptic density of the NMJ, most notably the receptor subunit GluRIIA, the scaffold protein dlg, and the signaling molecule dPAK are also expanded as is the density by EM. These postsynaptic changes are accompanied by a large change in the gross morpology of the synapse, including a reduction in bouton number. The changes in the nerve structure, however, seem to be an indirect consequence of the role of Leon in the muscle.

The strength of the paper is in the basic description of these phenotypes. The weaknesses of the paper are in the characterization of the electrophysiology and, above all, in the attempt to formulate a mechanistic explanation of the phenotype. There are small technical issues throughout, such as the failure to quantify Western blots and imprecisions in the description (such as equating Cactus or dlg staining with SSR), but where the manuscript really falls apart is from [Figure 5](#fig5){ref-type="fig"} on.

Major Criticisms:

[Figure 5](#fig5){ref-type="fig"}: it is not clear to me why they use the heterozygote as the control in panel A. The values for EJC amplitude and quantal content are much lower than the control values in panels B and C. Also, the values for miniEJC amplitude vary greatly from one genetic background to another, hovering around 700 in the D42 and 24B Gal4 lines and more like 900 in the +/19-2 \"control\". Because this value is the denominator by which they judge quantal content it is possible that the apparent decrease in quantal content is largely due to an increase in mini amplitude that they missed because the +/19-2 value is abnormally high. I would strongly recommend they include *w1118* controls, recorded on the same days, alongside all the measurements for genotypes presented so that one can distinguish effects of the genetic background from those of the mutations. They should use the method of failures to determine quantal content independently since there is good reason to suspect they are misled at present. The increase in quantal size cannot alone explain the decrease in EJC amplitude but might explain a homeostatic decrease in probability of release. In any case, in its current state, the electrophysiology is not interpretable and the final line of that section, which says something vague about correlating with the expansion phenotype, is not really an interpretation and it isn\'t clear what \"correlating\" refers to.

Nevertheless, the obvious explanation for the decreased EJC amplitude is that there are far fewer boutons present and therefore fewer release sites and less release. I don\'t understand why they do not make this point. That miniEJC frequency is normal may reflect a homeostatic compensation, but it seems inadequate to compensate for the sharp drop in bouton \#.

Subsection "Impaired electrophysiological properties at *leon* mutant NMJs" paragraph two: do the authors intend mEJC amplitude or EJC amplitude. Did they mean the driver by itself or the driver driving the transgene? This sentence was unclear.

The same paragraph overstates the result. EJC amplitude are not restored to wt levels (and the significance of the change is not tested statistically). What they mean to say is \"partially restores\" of \"improves relative to the mutant\" or something like that.

Mechanism: the manuscript does not describe the ubiquitination or a change in ubiquitination for any of the proteins that they claim are misregulated as a result of the leon mutations. They have only overexposed Western blots that are likely to be saturated and no accurate quantification of the levels of the postsynaptic proteins in [Figure 6](#fig6){ref-type="fig"}.

Re: [Figure 6](#fig6){ref-type="fig"}, one cannot equate Cactus staining with the SSR (see point re [Figure 3](#fig3){ref-type="fig"} also). It might label the entire SSR or it might not, but it would be best just to refer to the width of the cactus immunoreactive zone unless one also is going to do EM to look at the SSR or syndapin staining which might be OK as a surrogate for SSR.

The authors say that knockdown of syndapin has no effect on cactus or GluRIIA expansion but offer no evidence that their RNAi altered syndapin expression. Similarly, they base all the arguments in [Figure 6](#fig6){ref-type="fig"} on the effects of heterozygotes but do not indicate if those heterozygotes changed levels of the encoded protein and over-interpret a failure to alter a parameter as a lack of involvement of that protein in the expansions they observed. Since they do not know quantitatively if leon mutations have altered the levels of that protein, they cannot know if the heterozygous allele they use (a seemingly arbitrary decision) has had any impact on the level of the protein, decreased it back to control levels or not, or rendered it lower than controls. These experiments are not interpretable.

[Figure 7](#fig7){ref-type="fig"} comes the closest to a mechanistic understanding by implicating Ubqn in the pathway. The data are imperfect however since there is no quantification of the claimed increase in Ubqn in the *leon* mutants and the ability of Ubqn loss of function to prevent the expansion of the postsynaptic markers does not really prove that it was directly in the path of the changes. Presumably any protein that was required for the SSR or the PSD would be necessary regardless of whether it was regulated by Leon. Other specific issues for [Figure 7](#fig7){ref-type="fig"} include: In [Figure 7D](#fig7){ref-type="fig"}, FK2 intensity is measured; is this with background subtraction? Given the big change in overall levels this seems to be necessary, especially since the authors are emphasizing a synaptic decrease, but it is not mentioned in the text/methods. From [Figure 7E](#fig7){ref-type="fig"} the authors claim that Ubqn levels are upregulated in *leon* mutants. The change in band size is too subtle to tell, especially with the saturation of both the Ubqn and loading control bands. Either a quantification with several replicates or a shorter exposure blot would be necessary. From [Figure 7F](#fig7){ref-type="fig"} the authors claim that Ubqn immunostaining is increased in *leon* mutants, \"highly elevated at SSR rather than other regions\"; the magnification is too low to tell, and a quantification is necessary to demonstrate the robustness of the phenotype. If quantification cannot be done, please at least show multiple examples. Figure 7---figure supplement 2C: no loading control shown on the blots.

*Reviewer \#3:*

Ubiquitin-dependent proteolysis is a complex pathway of protein metabolism implicated in such diverse cellular functions. A late step of the process involves disassembly of the polyubiquitin chains on degraded proteins into ubiquitin monomers. USP5 disassembles branched polyubiquitin chains by a sequential exo mechanism, starting at the proximal end of the chain. Particularly, the enzyme is meant to disassemble free, substrate-unconjugated polyubiquitin chains to replenish the pool of mono-ubiquitin, and thus maintain cellular ubiquitin homeostasis.

The Chien lab recently published a first genetic analysis for USP5 in *Drosophila*, showing that Leon is essential for viability, and that *leon* mutants accumulate both free and substrate-conjugated polyubiquitin chains Proteasomal enzymatic activities were elevated in *leon* mutants, while proteasomal degradation of ubiquitinated substrates was impaired.

Here, the Chien lab executed an analysis of Leon function at the larval NMJ system. Core findings/experiments they present are 1) an expansion of the SSR muscle membrane infoldings and the size of postsynaptic glutamate receptor fields/PSD area due to a lack of muscle Leon function; 2) Western blots and immunostainings of dissected body wall muscles pointing towards increased levels of free and substrate-conjugated polyubiquitin chains; 3) based on TEVC recordings, an impairment of evoked release EJC amplitude and quantal content due to lack of postsynaptic muscle Leon; 4) heterozygous suppression of SSR outgrowth/GluRIIA receptor field outgrowth via dlg /dpak, creating arguments for accumulation of postsynaptic proteins to promote SSR expansion; 5) muscle knockdown of UBA-UBL ubiquitin receptor Ubqn suppressed expansions of Dlg rings and GluRIIA.

Per se, I am impressed by the severity of the phenotypes (SSR expansion, GluR fields) they report, and I think if appropriately revised this manuscript might become a strong candidate for *eLife*. My major concerns are the following:

1\) Can they exclude that they are looking at a \"heterochronic\" phenotype? In the case of dlg mutants, SSR formation is impaired throughout larval development when comparing precisely timed animals. However, as pupa formation is impaired or completely suppressed in dlg mutants, SSR ultimately growths to over a value found in wild type controls. Are their *leon* mutants undergoing pupa formation timely? They should compare precisely timed cohorts to make sure that really the pace of SSR expansion is increased here.

2\) Ubqn knockdown they apparently only tested within *leon* mutant background. How does the phenotype look like in wt background? Are they maybe just seeing the addition of two phenotypes here without any specific functional interaction? Anyway, I must confess that I cannot fully follow the mechanistic connection in between Leon and Ubqn.

3\) They should try to directly monitor a poly-U species of some relevant postsynaptic protein. This would make their case more convincing.

4\) Concerning the diameter of the GluRIIA fields they report: values appear very high. Can they exclude that they are imaging two or more super-imposed receptor fields as one?

5\) Somewhat surprisingly but not without example, they find mini amplitudes to be unchanged despite a severe increase of particularly GluRIIA. However, I was surprised to see a down-regulation of evoked release, means that quantal content is severely down here. Concerning the mechanistic basis of their electrophysiological phenotypes, they say: \"which correlates with its requirement in postsynaptic differentiation\" I am afraid this is insufficient.

6\) They state that both free polyubiquitin chains and ubiquitinated substrate proteins were changed in *leon* mutants. Is the availability of monomeric Ubiquitin determining their phenotype? Could they test for this?

7\) Why in [Figure 2A](#fig2){ref-type="fig"} much more poly-U signal when overexpressing the kinase dead ED Leon?

General comment: the manuscript clearly needs language editing. Moreover, the format of the figures is very diverse, and could be improved by e.g. showing blow ups of the respective GluRIIA phenotypes.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"USP5/Leon deubiquitinase confines postsynaptic growth by maintaining ubiquitin homeostasis through Ubiquilin\" for further consideration at *eLife*. Your revised article has been favorably evaluated by K VijayRaghavan (Senior editor), a Reviewing editor, and one reviewer.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below. Please make the textual changes suggested by his reviewer..

*Reviewer \#1:*

The manuscript is stronger, the electrophysiology more rigorous, and I also think it should be published. The phenotype is big, clear, and the genetics of rescue and RNAi are all very robust. The supplemental table with full statistics is very valuable, as is the inclusion of data from the cd8GFP reporter of the ssr. Some issues can (and should) be improved in the text. My chief concern is that the mechanism behind the phenotypes is not nearly as clear as the authors state. It is fine with me that some things remain poorly explained; but the authors need not try to make it appear as if the very modest changes in certain protein levels are sufficient to explain the phenoptyes or that the changes in bouton number can adequately explain what is happening to quantal content. Ubiquitin homeostasis and protein turn over are very complicated and broadly acting processes and not easily pinned down to the few proteins one looks at. By the end of the Results, a very strong case has been made for the importance of ubiquitination and Ubqn in regulating the development of the postsynapse. The remarks below are to help the authors avoid certain overstatements and premature conclusions in what is otherwise a very interesting and complete manuscript.

1\. In the subsection "Increases of postsynaptic proteins in *leon* mutants" and in the Discussion, it is a little awkward to say that each bouton houses tens of synapses (and it isn\'t always that many) because the term synapse is used sometimes to refer to the whole junction, sometimes to a bouton, and sometimes to each release site. If they say each bouton contains multiple release sites that face discrete receptor clusters the sentence will be less awkward.

2\. At the end of the subsection "Impaired electrophysiological properties at *leon* mutant NMJs": the change in bouton number (which this reviewer suggested as an explanation) doesn\'t really completely account for the change in the ejc amplitude and quantal content. It may account for some of it, but the ephys parameters are decreased by 50% or more (perhaps 65% for quantal content) and bouton \# is only decreased by 20-25%. If the density of release sites per bouton and size of boutons is really unchanged, there remains a mismatch that should still be acknowledged. It is tedious, but it would also help if the authors counted brp puncta in an entire NMJ to get a real value for release sites per NMJ. There may be changes in density, for example, that don\'t reach statistical significance on their own but, coupled with changes in bouton diameter and number might add up to a larger difference in release sites per NMJ. The bottom line is that it is ok if some of the ephys remains mysterious to explain - but this reviewer did not mean to imply that bouton number alone can actually explain the whole phenotype.

3\. There is obviously a disconnect between the very large changes in the SSR and dlg and gluR distributions, and the very small (and in the case of the weaker allele, insignificant) changes in the levels of Pak, dlg, and cact. I think it is fair to guess that many other proteins are increased in order to produce the large changes in the structure of the synapse. In addition, the fact that mutations in those proteins and others can prevent to increase in SSR or GluR markers does not in any way indicate that those proteins are part of the pathway through which leon is acting -- it only confirms those proteins are important for normal SSR and GluR development, i.e. they could as easily be part of parallel pathways regulating development as part of a linear pathway.

4\. At the end of the subsection "Suppression of *leon* mutant phenotypes by reducing Ubqn levels": the conclusion regarding the Ubqn increases seen in *leon* mutants is also overstated at this point in the paper. It is certainly likely that this contributes to the other phenotypes and the finding of a large increase in Ubqn in *leon* mutants and the finding that reducing Ubqn can prevent some or all of the phenotypes is important. But to really prove that the change in Ubqn is causative and not merely part of the phenotype, it needs the data in [Figure 8](#fig8){ref-type="fig"} that shows that overexpression of Ubqn in the muscle has the same phenotype as *leon* loss of function. (Ideally, they would also show that simply reducing Ubqn back to wildtype levels with RNAi or a heterozygote would be sufficient to reverse the leon phenotype. Instead they have used RNAi that nearly entirely remove the Ubqn.) The text for [Figure 7](#fig7){ref-type="fig"} should therefore be more circumspect or the big summary of the data for Ubqn in the pathway should wait till after the overexpression of Ubqn is presented in 8A,B.

10.7554/eLife.26886.024

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

*Reviewer \#1:*

*\[...\] Major comment:*

*-- My major comment is a lack of interpretation of the results in the Discussion. At the moment, the Discussion mostly recapitulates the data. How do the authors think Ubiquilin and free ubiquitin chains affect NMJ development?*

*As the levels of Dlg, Cac, etc are elevated at the earliest stages of NMJ development, it appears that either (a) the activity and/or levels of the master regulator of postsynaptic density formation, which remains unknown, are increased in leon mutants or (b) that the individual proteins that are found at the PSD and SSR are directly regulated by Ubiquilin and/or free ubiquitin chains. This is not discussed at the moment, but is essential for the reader to help interpret the consequences of these findings.*

We have revised the discussion on how free ubiquitin chains and Ubqn affect postsynaptic development in *leon* mutants (Discussion section paragraph three on the relationship of Ubqn and free Ub chains, and paragraph five on how SSR and PSD proteins accumulate). In addition, we have performed two additional experiments to address the relationship between free ubiquitin chains, Ubqn and individual SSR or PSD-localized proteins. First, overexpressing free ubiquitin chains also induced Ubqn accumulation ([Figure 10A, B](#fig10){ref-type="fig"}, also see response to reviewer\#1, point 2). Second, overexpression of Ubqn enhanced/stabilized ubiquitinated dPak, Dlg and Cact ([Figure 8D](#fig8){ref-type="fig"}). Overall, our model proposes (see [Figure 11](#fig11){ref-type="fig"}) that lack of *leon* deubiquitinating activity induces accumulation of free ubiquitin chains, which also contributes to Ubqn upregulation, and both accumulations lead to the accumulations of postsynaptic proteins that induce SSR and PSD growth. Based on this model, the role of Leon/USP5 is to maintain ubiquitin homeostasis, a process critical to postsynaptic growth.

*How could free ubiquitin chains alter protein levels / activity? Does overexpressing free ubiquitin chains lead to a similar increase in Ubiquilin levels or are these two events independent?*

We thank the reviewer for the suggestion of this experiment. We examined whether muscle overexpression of different ubiquitins (UbGG, UbAA and K48RUbAA) could regulate Ubqn levels. The result is that only overexpression of UbAA could upregulate Ubqn, indicating that excessive free ubiquitin chains induce Ubqn accumulation ([Figure 10A, B](#fig10){ref-type="fig"}). In contrast, Ubqn overexpression failed to accumulate free ubiquitin chains ([Figure 10C](#fig10){ref-type="fig"}). Thus, free ubiquitin chains and Ubqn seem to function in a linear pathway upon losing of Leon activity. However, overexpression of UbAA could not fully recapitulate the severity of *leon* phenotypes, which could be that UbAA overexpression hardly reaches the high-level free ubiquitin chains in *leon* mutants, or free ubiquitin chains account partially for Ubqn elevation in *leon* mutants. Ubqn overexpression enhanced the levels of ubiquitinated dPak, Dlg and Cact ([Figure 8D](#fig8){ref-type="fig"}). The elevated Ubqn could then bind to more ubiquitinated substrates like dPak, Dlg and Cact in postsynapses, leading to their increases in levels and activities. Therefore, this linear part of the pathway from free ubiquitin chains to Ubqn elevation could explain the substrate accumulation, although some other factors could not be excluded.

*In addition, is the increase in Ubiquilin due to a lack of free ubiquitin monomers? For instance, if the authors overexpress ubiquitin in leon mutants, can this rescue the increase in Ubiquilin levels? Does this affect NMJ development?*

We found no evidence to support that the increase of Ubqn is due to a lack of ubiquitin monomer. In *leon* mutants, while Ubqn was increased, the level of ubiquitin monomers was also increased by Western blot analysis ([Figure 2A](#fig2){ref-type="fig"}). Muscle overexpression of UbGG or K48RUbAA, which produced more ubiquitin monomers ([Figure 9B](#fig9){ref-type="fig"}), failed to alter Ubqn levels ([Figure 10A, B](#fig10){ref-type="fig"}). Thus, the increase of Ubqn is unlikely caused by the lack of ubiquitin monomers. Therefore, we did not perform the rescue experiment of overexpression of UbGG or K48RUbAA in *leon* mutants to suppress Ubqn levels and to affect NMJ development.

*Reviewer \#2:*

*\[...\] Major Criticisms:*

*[Figure 5](#fig5){ref-type="fig"}: it is not clear to me why they use the heterozygote as the control in panel A. The values for EJC amplitude and quantal content are much lower than the control values in panels B and C. Also, the values for miniEJC amplitude vary greatly from one genetic background to another, hovering around 700 in the D42 and 24B Gal4 lines and more like 900 in the +/19-2 \"control\". Because this value is the denominator by which they judge quantal content it is possible that the apparent decrease in quantal content is largely due to an increase in mini amplitude that they missed because the +/19-2 value is abnormally high. I would strongly recommend they include w1118 controls, recorded on the same days, alongside all the measurements for genotypes presented so that one can distinguish effects of the genetic background from those of the mutations. They should use the method of failures to determine quantal content independently since there is good reason to suspect they are misled at present.*

We respond to this comment with three points below:

1)The reason to perform electrophysiology recording with the heterozygous mutant *+/19-2* as the control is to avoid possible background mutations that might arise from the deletion allele. However, we also understand the reviewer's concern that *+/19-2* could have presented a phenotype in comparison to *w1118*. We therefore preformed new mEJC recording for *w1118, +/19-2* and *leon^[@bib1]^/19-2* and recorded three different genotypes on the same days (Indeed, all our electrophysiological recordings are always done in the same days for different genotypes). The mEJCs of *w1118* and *+/19-2* show little difference (689 v.s. 709 pA). The mEJC of *leon^[@bib1]^/19-2* showed some increases to *w1118* and *+/19-2,* although they are not statistical significant (p=0.3 and 0.39, respectively, by Student's *t* test) ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Taken together with data in [Figure 5](#fig5){ref-type="fig"}, it seems that mEJCs of *leon^1^/19-2* is likely slightly larger than controls.

2\) However, whether the difference in mEJCs is statistical significant or not depends on the genetic background. When performed with GAL4 driver backgrounds ([Figure 5B, C](#fig5){ref-type="fig"}), the increases are statistical significant, while without the GAL4 driver background, the increases are not statistical significant by comparison to *w1118* and *+/19-2* ([Figure 5A](#fig5){ref-type="fig"} and above). Therefore, we always perform electrophysiological recording with respective GAL4 control in rescue experiments.

3\) The slight increase in mEJCs, whether it is statistically significance or not, could not account for the large reduction in the quantal content, which is mainly due to the reduction in EJCs. As suggested by the reviewer, we also preformed failure analysis in *w1118, +/19-2* and *leon^[@bib1]^/19-2* and showed that the quantal content was dramatically decreased in *leon^[@bib1]^/19-2* ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Thus, the quantal content in *leon^[@bib1]^/19-2* is reduced as compared to both *w1118* and *+/19-2* with studies from two different measurements. The result is described in subsection "Impaired electrophysiological properties at *leon* mutant NMJs ".

*The increase in quantal size cannot alone explain the decrease in EJC amplitude but might explain a homeostatic decrease in probability of release. In any case, in its current state, the electrophysiology is not interpretable and the final line of that section, which says something vague about correlating with the expansion phenotype, is not really an interpretation and it isn\'t clear what \"correlating\" refers to.*

*Nevertheless, the obvious explanation for the decreased EJC amplitude is that there are far fewer boutons present and therefore fewer release sites and less release. I don\'t understand why they do not make this point. That miniEJC frequency is normal may reflect a homeostatic compensation, but it seems inadequate to compensate for the sharp drop in bouton \#.*

Due to severe developmental defects in *leon* mutant synapses, we agree that the electrophysiological results are difficult to reconcile in this manuscript. We thank the reviewer for pointing out one better explanation. We rewrote the sentence in the manuscript to describe that fewer boutons might be correlative to lower EJCs and quantal contents detected in *leon* mutants (subsection "Impaired electrophysiological properties at *leon* mutant NMJs").

*Subsection "Impaired electrophysiological properties at leon mutant NMJs" paragraph two: do the authors intend mEJC amplitude or EJC amplitude. Did they mean the driver by itself or the driver driving the transgene? This sentence was unclear.*

This sentence was really unclear.Actually, we reorganized this section.The sentence is shown as "The mEJC in *leon* mutants carrying *D42-GAL4* or *24B-GAL4* was significantly larger than that in respective GAL4 driver control, suggesting the mEJC increase in *leon* mutants might be sensitive to the variation in genetic backgrounds ([Figure 5B, C](#fig5){ref-type="fig"})."

*The same paragraph overstates the result. EJC amplitude are not restored to wt levels (and the significance of the change is not tested statistically). What they mean to say is \"partially restores\" of \"improves relative to the mutant\" or something like that.*

We agree it is a partial rescue andrewrote the sentence as "Postsynaptic Leon expression by *24B-GAL4* partially restored the EJC amplitude and the quantal content in *leon^[@bib1]^/19-2* ([Figure 5C](#fig5){ref-type="fig"}).". The statistical test for partial recue to *24B-GAL4* control is now indicated in [Figure 5C](#fig5){ref-type="fig"}.

*Mechanism: the manuscript does not describe the ubiquitination or a change in ubiquitination for any of the proteins that they claim are misregulated as a result of the leon mutations. They have only overexposed Western blots that are likely to be saturated and no accurate quantification of the levels of the postsynaptic proteins in [Figure 6](#fig6){ref-type="fig"}.*

To quantify protein levels for Dlg, dPak, and Cact, immunoblot intensities from three independent Western blots were averaged. The result suggests that the protein levels are significantly increased in the *leon^[@bib1]^/19-2* mutant and remained similar in *leon^2^/19-2* ([Figure 6E](#fig6){ref-type="fig"}, the quantifications are described in subsection "Suppression of leon mutant phenotypes by reducing postsynaptic proteins"). Therefore, we propose that both increase of protein levels and localization to postsynaptic sites are two major regulations. We have also changed images with shorter exposure for [Figure 6E](#fig6){ref-type="fig"}.

Regarding ubiquitination, the ubiquitinated proteins are difficult to detect in Western blot for body wall muscle extracts. We have tried to overexpress tagged transgenes for Ub and Dlg or dPak in muscles and still had difficulty to detect any changes in *leon* mutants. One possibility is that the pools of proteins in postsynaptic sites are not sufficient for detecting any change. We also tried to knockdown of Leon in S2 cells by dsRNA for examing Dlg, dPak and Cact ubiquitination. While 90% of Leon was depleted in S2 cells, such knockdown efficiency is not sufficient to disrupt ubiquitin homeostasis in S2 cells, as free ubiquitin chains and ubiquitinated substrates could not be detected. One alternative experiment that we have performed is the detection of protein ubiquitination with or without Ubqn in S2 cells ([Figure 8D](#fig8){ref-type="fig"}). We found that ubiquitinations of dPak, Dlg and Cact were elevated when Ubqn was overexpressed. Thus, Ubqn is the important player in mediating protein accumulation in *leon* mutants. The results are described in a paragraph two of subsection "Ubqn induces and associates with ubiquitinated postsynaptic proteins", and discussed in paragraph five of the Discussion section.

*Re: [Figure 6](#fig6){ref-type="fig"}, one cannot equate Cactus staining with the SSR (see point re [Figure 3](#fig3){ref-type="fig"} also). It might label the entire SSR or it might not, but it would be best just to refer to the width of the cactus immunoreactive zone unless one also is going to do EM to look at the SSR or syndapin staining which might be OK as a surrogate for SSR.*

We agree with the reviewer's concern, and performing EM to assess the genetic suppression is an unlikely task, considering there are so many genetic assays. We were not able to obtain Syndapin antibodies for the assessment, either. We therefore used the membrane form of GFP that is enriched in SSR to repeat the genetic suppression test ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Also, we change the term SSR to Cact-positive zones.

*The authors say that knockdown of syndapin has no effect on cactus or GluRIIA expansion but offer no evidence that their RNAi altered syndapin expression.*

The *UAS-SyndRNAi\#1*, used in previous submitted manuscript, is efficient in knockdown as shown by RT-PCR (see [Author response image 1](#fig12){ref-type="fig"}). However, we decide to remove the results about the non-suppression by *Syndapin* knockdown, which provides no extra meaning to the manuscript.10.7554/eLife.26886.022Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.26886.022](10.7554/eLife.26886.022)

*Similarly, they base all the arguments in [Figure 6](#fig6){ref-type="fig"} on the effects of heterozygotes but do not indicate if those heterozygotes changed levels of the encoded protein and over-interpret a failure to alter a parameter as a lack of involvement of that protein in the expansions they observed. Since they do not know quantitatively if leon mutations have altered the levels of that protein, they cannot know if the heterozygous allele they use (a seemingly arbitrary decision) has had any impact on the level of the protein, decreased it back to control levels or not, or rendered it lower than controls. These experiments are not interpretable.*

The alleles we used for *dlg, dpak, pll, dl* and *cact* in [Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} are all documented null alleles that have been reported (Albin and Davis, 2004; Heckscher et al., 2007; Zhang et al., 2007). Heterozygous mutants showed a suppression effect on one or the other phenotype (Cact/Dlg or GluRIIA expansion) in *leon* mutants. Thus, whether protein levels are reduced or not, they should have reduced the gene activity in the heterozygous background. Nevertheless, we also tested the RNAi knockdown of *dlg, dpak, pll, dl* and *cact* in muscles of the *leon* mutants, and show the effect on suppression of mCD8GFP-labled SSR or GluRIIA expansions ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). These RNAi lines have been used in other studies (Dent et al., 2015; Sun and Irvine, 2011; Zhou et al., 2015), except *pelle* that was examined in this study ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). The results showed almost the same suppression effects as by heterozygous mutants. In addition, *dpak* knockdown further suppressed mCD8GFP-labled SSR expansion, in consistent with previous study in which dPak regulates GluRIIA abundance and SSR formation (Albin and Davis, 2004).

*[Figure 7](#fig7){ref-type="fig"} comes the closest to a mechanistic understanding by implicating Ubqn in the pathway. The data are imperfect however since there is no quantification of the claimed increase in Ubqn in the leon mutants and the ability of Ubqn loss of function to prevent the expansion of the postsynaptic markers does not really prove that it was directly in the path of the changes. Presumably any protein that was required for the SSR or the PSD would be necessary regardless of whether it was regulated by Leon.*

We quantified three independently performed Western blots and immunostaining of Ubqn ([Figure 7C and 7D](#fig7){ref-type="fig"}, respectively, the quantification results are described in subsection "Suppression of leon mutant phenotypes by reducing Ubqn levels"). Both assays showed that the Ubqn levels were increased in hypomorphic *leon^[@bib2]^/19-2* and null *leon^[@bib1]^/19-2*.We address that Ubqn is in the Leon/USP5 pathway with following data: (1) The Ubqn level increased in *leon* mutants by both Western blots and immunostaining assays ([Figure 7C, D](#fig7){ref-type="fig"}), and the increases are more specific to synaptic areas than in overall muscles; (2) Muscle knockdown of *Ubqn* suppressed *leon* mutant phenotypes in SSR and PSD expansions ([Figure 7A, B](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1B, C](#fig7s1){ref-type="fig"}); (3) Muscle overexpression of *Ubqn* caused expansions of Dlg-positive zone and GluRIIA diameter ([Figure 8A, B](#fig8){ref-type="fig"}); (4) Ubqn bound and stabilized ubiquitinated proteins that are increased in *leon* mutants ([Figure 8C, D](#fig8){ref-type="fig"}). Taken together, Ubqn is a critical player in mediating *leon* mutant phenotypes.

*Other specific issues for [Figure 7](#fig7){ref-type="fig"} include: In [Figure 7D](#fig7){ref-type="fig"}, FK2 intensity is measured; is this with background subtraction? Given the big change in overall levels this seems to be necessary, especially since the authors are emphasizing a synaptic decrease, but it is not mentioned in the text/methods.*

We think that the FK2 signals are present in both postsynaptic sites as well as in muscle, and both are affected in *Ubqn* knockdown. Therefore, we did not treat the muscle signals as background. We now show quantifications of FK2 intensities for synapses as well as muscles ([Figure 7B](#fig7){ref-type="fig"}, bottom two panels).

*From [Figure 7E](#fig7){ref-type="fig"} the authors claim that Ubqn levels are upregulated in leon mutants. The change in band size is too subtle to tell, especially with the saturation of both the Ubqn and loading control bands. Either a quantification with several replicates or a shorter exposure blot would be necessary.*

We replaced it with a new Western blot image and quantified Ubqn levels (normalized to α-Tub internal control) from three independent experiments ([Figure 7C](#fig7){ref-type="fig"}, the quantifications are described in subsection "Suppression of leon mutant phenotypes by reducing Ubqn levels").

*From [Figure 7F](#fig7){ref-type="fig"} the authors claim that Ubqn immunostaining is increased in leon mutants, \"highly elevated at SSR rather than other regions\"; the magnification is too low to tell, and a quantification is necessary to demonstrate the robustness of the phenotype. If quantification cannot be done, please at least show multiple examples.*

We showed higher magnification figures in Ubqn single channel and used dashed lines to outline the Cact-positive regions (not shown in the figure) for quantification. We also quantified the mean intensity of Ubqn in muscles and Cact-positive zones in wild type and *leon* mutants as suggested ([Figure 7D](#fig7){ref-type="fig"}). The result is also described in subsection "Suppression of leon mutant phenotypes by reducing Ubqn levels".

*Figure 7---figure supplement 2C: no loading control shown on the blots.*

We have added loading controls ([Figure 8C](#fig8){ref-type="fig"}).

*Reviewer \#3:*

*\[...\] 1) Can they exclude that they are looking at a \"heterochronic\" phenotype? In the case of dlg mutants, SSR formation is impaired throughout larval development when comparing precisely timed animals. However, as pupa formation is impaired or completely suppressed in dlg mutants, SSR ultimately growths to over a value found in wild type controls. Are their leon mutants undergoing pupa formation timely? They should compare precisely timed cohorts to make sure that really the pace of SSR expansion is increased here.*

We noticed that the entire larval stage in the *leon^[@bib1]^/19-2* mutant was one day longer than wild type. The expansion of SSR and PSD in the *leon^[@bib1]^/19-2* mutants examined in the late third instar stage may be a consequence of extra growth. We have performed the experiment as suggested by the reviewer to compare SSR and PSD phenotypes between control and *leon* mutants at 72h, 96h, and 120h after egg laying (AEL). Apparently, *leon* mutants presented enlargement of PSD and SSR as early as 72h AEL, as the Cact-positive zone and GluRIIA clusters are significantly larger than controls, and the differences are further enhanced at later stages ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). The description for this result could be found in paragraph four of subsection "Increases of postsynaptic proteins in *leon* mutants".

*2) Ubqn knockdown they apparently only tested within leon mutant background. How does the phenotype look like in wt background? Are they maybe just seeing the addition of two phenotypes here without any specific functional interaction? Anyway, I must confess that I cannot fully follow the mechanistic connection in between Leon and Ubqn.*

Muscle *Ubqn* knockdown in the wildtype background had no effect on SSR-localized Dlg and PSD-localized GluRIIA ([Figure 8A-B](#fig8){ref-type="fig"}). Thus, the suppression of *leon* mutant phenotypes by *Ubqn* knockdown are not the summation of two phenotypes. The explanation for the connection between *leon* and *Ubqn* could be found in response to reviewer\#1, point 2, and more thoroughly in Discussion (paragraphs three and five). Briefly, elevated free ubiquitin chains in *leon* mutants induced elevation of Ubqn levels. Accumulated Ubqn stabilizes ubiquitinated postsynaptic proteins to cause NMJ defects.

*3) They should try to directly monitor a poly-U species of some relevant postsynaptic protein. This would make their case more convincing.*

It has been difficult to detect ubiquitinated dPak, Dlg and Cact in body wall muscle preparation of wildtype or *leon* mutants, even with overexpression of Ub transgene. However, in S2 cells, expression of Ubqn stabilizes ubiquitinated dPak, Dlg and Cact, as compared to those without Ubqn overexpression. These results were shown in [Figure 8D](#fig8){ref-type="fig"} and described in paragraph two of subsection "Ubqn induces and associates with ubiquitinated postsynaptic proteins". These results are consistent with that accumulation of Ubqn, such as in *leon* mutants, stabilizes ubiquitinated dPak, Dlg and Cact. Also see response to reviewer\#2, point 5.

*4) Concerning the diameter of the GluRIIA fields they report: values appear very high. Can they exclude that they are imaging two or more super-imposed receptor fields as one?*

In our analysis,the diameter of GluRIIA clusters is about 0.63 µm in wild type third instar larvae, which is comparable to GluR cluster diameters in a previous report from Graeme Davis's group, showing that the GluRIIC diameter is about 0.78 µm in third instar larvae and the GluRIIA diameter is about 0.52 µm in second instar larvae (Pielage et al., 2006). In our study, we were very cautious to select "isolated" GluRIIA puncta in both mutants and wild type. The methodology is described in Materials and methods ("Quantifications"). Briefly,Z stacks of GluRIIA images were scanned with 0.5 µm intervals. Isolated puncta in different Z sections were selected for scoring, thus avoiding super-imposed ones.

*5) Somewhat surprisingly but not without example, they find mini amplitudes to be unchanged despite a severe increase of particularly GluRIIA. However, I was surprised to see a down-regulation of evoked release, means that quantal content is severely down here. Concerning the mechanistic basis of their electrophysiological phenotypes, they say: \"which correlates with its requirement in postsynaptic differentiation\" I am afraid this is insufficient.*

We think it is not easy to explain the down-regulation of evoked release through postsynaptic structural defects. One possible explanation is that the overall bouton number was decreased in *leon* mutants, leading to the decreased evoked response (as suggested by reviewer 2). Thus, the description is rewritten as "As postsynaptic expression of Leon also suppressed bouton reduction in the *leon* mutant ([Figure 1E, 1F](#fig1){ref-type="fig"}), the reduction of the EJC amplitude and the quantal content could be attributed to the reduction of the bouton and hence the release sites in *leon* mutants".

*6) They state that both free polyubiquitin chains and ubiquitinated substrate proteins were changed in leon mutants. Is the availability of monomeric Ubiquitin determining their phenotype? Could they test for this?*

Muscle expression of K48R-UbAA, which mimics the accumulation of mono-ubiquitin but not K48-linked polyubiquitin chains, generates large amounts of ubiquitin monomer ([Figure 9B](#fig9){ref-type="fig"}, lane 4). However, it cannot promote SSR and PSD expansion. Instead, UbAA that could form free ubiquitin chains (lane 3) promotes SSR and PSD expansion. While ubiquitin monomers were increased in *leon* mutants ([Figure 2A](#fig2){ref-type="fig"}), elevated ubiquitin monomers seem have no contribution to SSR and PSD expansion.

*7) Why in [Figure 2A](#fig2){ref-type="fig"} much more poly-U signal when overexpressing the kinase dead ED Leon?*

We think that ED-Leon could associate with polyubiquitin chains but fail to disassemble polyubiquitin chains due to inactivation of the enzymatic activity. It is possible that binding to ED-Leon sequesters ubiquitinated substrates from degradation and leads to their accumulation.

*General comment: the manuscript clearly needs language editing. Moreover, the format of the figures is very diverse, and could be improved by e.g. showing blow ups of the respective GluRIIA phenotypes.*

The revised manuscript has been reviewed by an in-house English editor. Also, in the revised manuscript, GluRIIA images are enlarged, and representative enlarged images are shown in [Figure 3B](#fig3){ref-type="fig"} (right panels). We also made figure and bar graph format consistent throughout the text.

\[Editors' note: the author responses to the second round of peer review follow.\]

*The manuscript is stronger, the electrophysiology more rigorous, and I also think it should be published. The phenotype is big, clear, and the genetics of rescue and RNAi are all very robust. The supplemental table with full statistics is very valuable, as is the inclusion of data from the cd8GFP reporter of the ssr. Some issues can (and should) be improved in the text. My chief concern is that the mechanism behind the phenotypes is not nearly as clear as the authors state. It is fine with me that some things remain poorly explained; but the authors need not try to make it appear as if the very modest changes in certain protein levels are sufficient to explain the phenoptyes or that the changes in bouton number can adequately explain what is happening to quantal content. Ubiquitin homeostasis and protein turn over are very complicated and broadly acting processes and not easily pinned down to the few proteins one looks at. By the end of the Results, a very strong case has been made for the importance of ubiquitination and Ubqn in regulating the development of the postsynapse. The remarks below are to help the authors avoid certain overstatements and premature conclusions in what is otherwise a very interesting and complete manuscript.*

*1. In the subsection "Increases of postsynaptic proteins in leon mutants" and in the Discussion, it is a little awkward to say that each bouton houses tens of synapses (and it isn\'t always that many) because the term synapse is used sometimes to refer to the whole junction, sometimes to a bouton, and sometimes to each release site. If they say each bouton contains multiple release sites that face discrete receptor clusters the sentence will be less awkward.*

Following the reviewer's suggestion, we modified the sentences as "At NMJs, each bouton contains multiple release sites paired with discrete receptor clusters that..." and "Each bouton contains multiple release sites where neurotransmitters...".

*2. At the end of the subsection "Impaired electrophysiological properties at leon mutant NMJs": the change in bouton number (which this reviewer suggested as an explanation) doesn\'t really completely account for the change in the ejc amplitude and quantal content. It may account for some of it, but the ephys parameters are decreased by 50% or more (perhaps 65% for quantal content) and bouton \# is only decreased by 20-25%. If the density of release sites per bouton and size of boutons is really unchanged, there remains a mismatch that should still be acknowledged. It is tedious, but it would also help if the authors counted brp puncta in an entire NMJ to get a real value for release sites per NMJ. There may be changes in density, for example, that don\'t reach statistical significance on their own but, coupled with changes in bouton diameter and number might add up to a larger difference in release sites per NMJ. The bottom line is that it is ok if some of the ephys remains mysterious to explain - but this reviewer did not mean to imply that bouton number alone can actually explain the whole phenotype.*

We quantified the Brp number per NMJ: *w^1118^*, 731.6 ± 31.6; *leon^2^/19-2*, 631.9 ± 28.1; *leon^1^/19-2*, 619.5 ± 31.1; n = 10 for all genotypes; Statistics by Student's t test showed that both leon mutants were p \< 0.05 in comparison to *w^1118^*. These reductions of Brp numbers are about 15%, and are close to the 20% reduction in the bouton numbers in *leon* mutants. As EJC and quantal content were decreased by 50%, we think reduction of bouton and the releasing sites contribute partly to the reduction of EJC and quantal content. We present this quantification and modified the description accordingly.

*3. There is obviously a disconnect between the very large changes in the SSR and dlg and gluR distributions, and the very small (and in the case of the weaker allele, insignificant) changes in the levels of Pak, dlg, and cact. I think it is fair to guess that many other proteins are increased in order to produce the large changes in the structure of the synapse. In addition, the fact that mutations in those proteins and others can prevent to increase in SSR or GluR markers does not in any way indicate that those proteins are part of the pathway through which leon is acting -- it only confirms those proteins are important for normal SSR and GluR development, i.e. they could as easily be part of parallel pathways regulating development as part of a linear pathway.*

We agree that many proteins are altered in *leon* mutants, and we are only able to examine a handful of them. The slight but not dramatic increases in protein levels of dPak, Dlg and Cact as shown by Western blots could explain at least partly the protein accumulation in postsynaptic specializations. Other mechanisms such as protein recruitment could be also involved. We modified the texts to describe this idea in the Results and Discussion. Regarding whether these proteins are part of the Leon pathway or not, we have not implied that Leon is in direct regulation of these proteins. Instead, we have included Ubqn in the model to explain how these proteins might be stabilized and contribute to postsynaptic structural expansions (Discussion, and [Figure 11](#fig11){ref-type="fig"} for a schematic model).

4\. At the end of the subsection "Suppression of leon mutant phenotypes by reducing Ubqn levels": the conclusion regarding the Ubqn increases seen in leon mutants is also overstated at this point in the paper. It is certainly likely that this contributes to the other phenotypes and the finding of a large increase in Ubqn in leon mutants and the finding that reducing Ubqn can prevent some or all of the phenotypes is important. But to really prove that the change in Ubqn is causative and not merely part of the phenotype, it needs the data in [Figure 8](#fig8){ref-type="fig"} that shows that overexpression of Ubqn in the muscle has the same phenotype as leon loss of function. (Ideally, they would also show that simply reducing Ubqn back to wildtype levels with RNAi or a heterozygote would be sufficient to reverse the leon phenotype. Instead they have used RNAi that nearly entirely remove the Ubqn.) The text for [Figure 7](#fig7){ref-type="fig"} should therefore be more circumspect or the big summary of the data for Ubqn in the pathway should wait till after the overexpression of Ubqn is presented in 8A,B.

We modified the conclusion for Fig. 7. This modified text was shown in Lines 431-433, as "These results are consistent with that the increase in the Ubqn level in *leon* mutants could mediate expansions of Dlg-positive zones, dPak patches and GluRIIA clusters in *leon* mutants."
